<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation - Bruins Slot, KMH - 2018 | Cochrane Library</title> <meta content="Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation - Bruins Slot, KMH - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008980.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation - Bruins Slot, KMH - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008980.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008980.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation" name="citation_title"/> <meta content="Karsten MH Bruins Slot" name="citation_author"/> <meta content="Oslo University Hospital" name="citation_author_institution"/> <meta content="kbruinsslot@yahoo.no" name="citation_author_email"/> <meta content="Eivind Berge" name="citation_author"/> <meta content="Oslo University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD008980.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008980.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008980.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008980.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Atrial Fibrillation [*complications]; Embolism [*prevention &amp; control]; Factor Xa Inhibitors [*therapeutic use]; Intracranial Embolism [*prevention &amp; control]; Randomized Controlled Trials as Topic; Stroke [prevention &amp; control]; Vitamin K [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008980.pub3&amp;doi=10.1002/14651858.CD008980.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008980\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008980\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","pt","ms","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008980.pub3",title:"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation",firstPublishedDate:"Mar 6, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008980.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008980.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008980.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008980.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008980.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008980.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008980.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008980.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008980.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008980.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9657 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008980.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0125"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-sec-0116"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/appendices#CD008980-sec-0130"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/table_n/CD008980StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/table_n/CD008980StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information#CD008980-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Karsten MH Bruins Slot</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information#CD008980-cr-0003">Eivind Berge</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information/en#CD008980-sec-0148">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008980.pub3">https://doi.org/10.1002/14651858.CD008980.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008980-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008980-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008980-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008980-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008980-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008980-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008980-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008980-abs-0001" lang="en"> <section id="CD008980-sec-0001"> <h3 class="title" id="CD008980-sec-0001">Background</h3> <p>Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in treatment guidelines for preventing stroke and systemic embolic events in people with atrial fibrillation (AF). This is an update of a Cochrane review previously published in 2013. </p> </section> <section id="CD008980-sec-0002"> <h3 class="title" id="CD008980-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of treatment with factor Xa inhibitors versus VKAs for preventing cerebral or systemic embolic events in people with AF. </p> </section> <section id="CD008980-sec-0003"> <h3 class="title" id="CD008980-sec-0003">Search methods</h3> <p>We searched the trials registers of the Cochrane Stroke Group and the Cochrane Heart Group (September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (August 2017), MEDLINE (1950 to April 2017), and Embase (1980 to April 2017). We also contacted pharmaceutical companies, authors and sponsors of relevant published trials. We used outcome data from marketing authorisation applications of apixaban, edoxaban and rivaroxaban that were submitted to regulatory authorities in Europe and the USA. </p> </section> <section id="CD008980-sec-0004"> <h3 class="title" id="CD008980-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that directly compared the effects of long‐term treatment (lasting more than four weeks) with factor Xa inhibitors versus VKAs for preventing cerebral and systemic embolism in people with AF. </p> </section> <section id="CD008980-sec-0005"> <h3 class="title" id="CD008980-sec-0005">Data collection and analysis</h3> <p>The primary efficacy outcome was the composite endpoint of all strokes and systemic embolic events. Two review authors independently extracted data, and assessed the quality of the trials and the risk of bias. We calculated a weighted estimate of the typical treatment effect across trials using the odds ratio (OR) with 95% confidence interval (CI) by means of a fixed‐effect model. In case of moderate or high heterogeneity of treatment effects, we used a random‐effects model to compare the overall treatment effects. We also performed a pre‐specified sensitivity analysis excluding any open‐label studies. </p> </section> <section id="CD008980-sec-0006"> <h3 class="title" id="CD008980-sec-0006">Main results</h3> <p>We included data from 67,688 participants randomised into 13 RCTs. The included trials directly compared dose‐adjusted warfarin with either apixaban, betrixaban, darexaban, edoxaban, idraparinux, idrabiotaparinux, or rivaroxaban. The majority of the included data (approximately 90%) was from apixaban, edoxaban, and rivaroxaban. </p> <p>The composite primary efficacy endpoint of all strokes (both ischaemic and haemorrhagic) and non‐central nervous systemic embolic events was reported in all of the included studies. Treatment with a factor Xa inhibitor significantly decreased the number of strokes and systemic embolic events compared with dose‐adjusted warfarin in participants with AF (OR 0.89, 95% CI 0.82 to 0.97; 13 studies; 67,477 participants; high‐quality evidence). </p> <p>Treatment with a factor Xa inhibitor significantly reduced the number of major bleedings compared with warfarin (OR 0.78, 95% CI 0.73 to 0.84; 13 studies; 67,396 participants; moderate‐quality evidence). There was, however, statistically significant and high heterogeneity (I<sup>2</sup> = 83%). When we repeated this analysis using a random‐effects model, it did not show a statistically significant decrease in the number of major bleedings (OR 0.88, 95% CI 0.66 to 1.17). A pre‐specified sensitivity analysis excluding all open‐label studies showed that treatment with a factor Xa inhibitor significantly reduced the number of major bleedings compared with warfarin (OR 0.75, 95% CI 0.69 to 0.81), but high heterogeneity was also observed in this analysis (I<sup>2</sup> = 72%). The same sensitivity analysis using a random‐effects model also showed a statistically significant decrease in the number of major bleedings in participants treated with factor Xa inhibitors (OR 0.76, 95% CI 0.60 to 0.96). </p> <p>Treatment with a factor Xa inhibitor significantly reduced the risk of intracranial haemorrhages (ICHs) compared with warfarin (OR 0.50, 95% CI 0.42 to 0.59; 12 studies; 66,259 participants; high‐quality evidence). We observed moderate, but statistically significant heterogeneity (I<sup>2</sup> = 55%). The pre‐specified sensitivity analysis excluding open‐label studies showed that treatment with a factor Xa inhibitor significantly reduced the number of ICHs compared with warfarin (OR 0.47, 95% CI 0.40 to 0.56), with low, non‐statistically significant heterogeneity (I<sup>2</sup> = 27%). </p> <p>Treatment with a factor Xa inhibitor also significantly reduced the number of all‐cause deaths compared with warfarin (OR 0.89, 95% 0.83 to 0.95; 10 studies; 65,624 participants; moderate‐quality evidence). </p> </section> <section id="CD008980-sec-0007"> <h3 class="title" id="CD008980-sec-0007">Authors' conclusions</h3> <p>Treatment with factor Xa inhibitors significantly reduced the number of strokes and systemic embolic events compared with warfarin in people with AF. The absolute effect of factor Xa inhibitors compared with warfarin treatment was, however, rather small. Factor Xa inhibitors also reduced the number of ICHs, all‐cause deaths and major bleedings compared with warfarin, although the evidence for a reduction in the latter is less robust. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008980-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008980-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008980-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008980-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008980-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008980-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008980-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008980-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008980-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008980-abs-0005" lang="en"> <h3>Comparing two types of blood‐thinning drugs, factor Xa inhibitors and vitamin K antagonists, to prevent blood clots in people with atrial fibrillation </h3> <p><b>Review question</b> </p> <p>We compared the benefits and harms of two types of so‐called "blood‐thinning" drugs (factor Xa inhibitors and vitamin K antagonists) in people with atrial fibrillation. </p> <p><b>Background</b> </p> <p>People with atrial fibrillation, a condition that causes the heart to beat irregularly, are at an increased risk of getting blood clots. Such clots can block blood vessels and cause severe organ damage in the brain (stroke) or other organs. Various guidelines recommend that people with atrial fibrillation should be treated with "blood‐thinning" drugs such as factor Xa inhibitors or vitamin K antagonists (e.g. warfarin) because these drugs can prevent the formation of blood clots. Serious side effects of these drugs are bleedings (e.g. into the brain) that can cause serious disability or even death. </p> <p><b>Study characteristics</b> </p> <p>We searched various sources up to 29 August 2017 and included 13 studies that involved 67,688 people with atrial fibrillation who received either a factor Xa inhibitor or a vitamin K antagonist. All included people were adults and on average aged between 65 and 74 years. Approximately one‐third were women. </p> <p><b>Key results</b> </p> <p>We found that factor Xa inhibitors when compared with warfarin, which was used as comparator in all trials, reduced the number of strokes in people with atrial fibrillation. This reduction was, however, rather small. Factor Xa inhibitors also appeared to reduce the number of serious bleedings (including those into the brain) and the number of people dying from any cause compared with warfarin. </p> <p><b>Quality of evidence</b> </p> <p>We considered the quality of evidence in our review as moderate to high. The studies that we included were generally large to very large. We found that the results from the larger studies were generally similar and this strengthened our findings. Finally, we are confident that we included all relevant studies in our review and did not miss any important studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008980-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008980-sec-0125"></div> <h3 class="title" id="CD008980-sec-0126">Implications for practice</h3> <section id="CD008980-sec-0126"> <p> <ul id="CD008980-list-0014"> <li> <p>Overall, there is a net clinical benefit of treatment with factor Xa inhibitors in people with atrial fibrillation (AF), as treatment seems to be associated with a relatively small reduction in the number of strokes and systemic embolic events and a more pronounced reduction in the number of intracranial haemorrhages, other major bleedings and deaths compared with dose‐adjusted warfarin. </p> </li> </ul> <ul id="CD008980-list-0015"> <li> <p>Despite the apparent overall net clinical benefit, the currently available efficacy and safety data do not provide sufficient evidence to determine the most optimal factor Xa inhibitor, since head‐to‐head studies have not yet been performed. </p> </li> </ul> <ul id="CD008980-list-0016"> <li> <p>Caution is needed when drawing any firm conclusions concerning the net clinical benefit for people with a 'very low risk' for thromboembolic events (i.e. low CHA2DS2‐VASc scores), people with severe renal impairment, or people on haemodialysis, as these populations were generally not included in the studies analysed in our review. </p> </li> </ul> </p> </section> <h3 class="title" id="CD008980-sec-0127">Implications for research</h3> <section id="CD008980-sec-0127"> <p>Future studies could aim to:</p> <p> <ul id="CD008980-list-0017"> <li> <p>further determine the effectiveness and safety of long‐term anticoagulation treatment with a factor Xa inhibitor (i.e. beyond two years) in a 'real world' population of people with AF; </p> </li> <li> <p>directly compare the efficacy and safety of two (or more) factor Xa inhibitors;</p> </li> <li> <p>identify means of further minimising the risk of major and non‐major bleedings without reducing the benefit of factor Xa inhibitors; </p> </li> <li> <p>further assess the efficacy and safety of factor Xa inhibitors in people with a 'very low risk' for thromboembolic events (i.e. low CHA<sub>2</sub>DS<sub>2</sub>‐VASc scores); </p> </li> <li> <p>provide more data on the effectiveness, health‐related quality of life and cost‐effectiveness of treatment with factor Xa inhibitors compared with VKAs for prevention of thromboembolic events in people with AF, also in various settings (e.g. comparing centres with 'high' versus 'low' quality warfarin administration); </p> </li> <li> <p>further develop and validate reliable assays to monitor the effect of factor Xa inhibitors (e.g. prior to acute surgery or to assess adherence to therapy). </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008980-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008980-sec-0029"></div> <div class="table" id="CD008980-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor Xa inhibitors compared with vitamin K antagonists for preventing stroke and other systemic embolic events in patient with atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment </p> <p><b>Settings:</b> hospital‐based setting </p> <p><b>Intervention:</b> factor Xa inhibitor<sup>1</sup> </p> <p><b>Comparison:</b> dose‐adjusted vitamin K antagonist<sup>2</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Warfarin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Factor Xa inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke and other systemic embolic events</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> <p>(33 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> </p> <p>(0.82 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67477<br/> (13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All strokes</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> <p>(29 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> </p> <p>(0.81 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67449<br/> (13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleedings</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> <p>(43 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b> </p> <p><b>(</b>0.73 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67396<br/> (13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intracranial haemorrhages</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> <p>(8 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.50</b> </p> <p>(0.42 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66259<br/> (12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause deaths</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> <p>(67 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> </p> <p>(0.83 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65624<br/> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1 The 13 studies included in this review studied the following types of oral and parenteral factor Xa inhibitors: edoxaban, rivaroxaban, apixaban, edoxaban, betrixaban, darexaban, idraparinux and idrabiotaparinux. Assumed risk calculated from pooled data from warfarin treatment arms (mean) of included studies.</sup> </p> <p><sup>2 All included studies used warfarin with a target INR 2.0‐3.0 as active comparator. Three studies performed in Japan had a target INR of 1.6‐2.6 and 2.0‐2.6 in participants aged &gt; 70 years.</sup> </p> <p><sup>3 High, statistically significant heterogeneity was observed in the initial analysis and in pre‐specified sensitivity analysis excluding all open‐label studies (i.e. the prematurely halted AMADEUS trial). Some other heterogeneity might be explained by baseline differences in the included populations in the three largest trials (ROCKET AF, ENGAGE TIMI‐AF and ARISTOTLE). See section <i>Effects of Interventions, Major bleedings</i> for further discussion.</sup> </p> <p><sup>4 High, statistically significant heterogeneity was observed in the initial analysis. No statistically significant heterogeneity was observed in a pre‐specified sensitivity analysis in which data from all open‐label studies were excluded (i.e. prematurely halted AMADEUS trial).</sup> </p> <p><sup>5 Outcome not reported in three trials and was missing/unknown for some randomised participants (up to 2.1% ) in some of the other included trials.</sup> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008980-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008980-sec-0030"></div> <section id="CD008980-sec-0031"> <h3 class="title" id="CD008980-sec-0031">Description of the condition</h3> <p>Atrial fibrillation (AF) is the most common type of arrhythmia in adults and becomes more common with increased age (<a href="./references#CD008980-bbs2-0040" title="GoAS , HylekEM , PhilipsKA , Henault , LE , SelbyJV , SingerDE . Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA2001;285:2370‐5. ">Go 2001</a>). The prevalence of AF is estimated at around 2% to 3% of the adult population (<a href="./references#CD008980-bbs2-0049" title="KirchhofP , AuricchioA , BaxJ , CrijnsH , CammJ , DienerH‐C , et al. Outcome parameters for trials in atrial ﬁbrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). European Heart Journal2007;28:2803‐17. ">Kirchhof 2007</a>; <a href="./references#CD008980-bbs2-0042" title="HaimM , HoshenM , RegesO , RabiY , BalicerR , LeibowitzM . Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non‐valvular atrial fibrillation. Journal of the American Heart Association2015;4:e001486. ">Haim 2015</a>). The lifetime risk for developing AF is approximately one in four for people aged 40 years and older (<a href="./references#CD008980-bbs2-0056" title="Lloyd‐JonesDM , WangTJ , LeipEP , LarsonMG , LevyD , VasanRS , et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation2004;110:1042‐6. ">Lloyd‐Jones 2004</a>; <a href="./references#CD008980-bbs2-0045" title="HeeringaJ , Van derKuipDA , HofmanA , KorsJA , VanHerpenG , StrickerBH , et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European Heart Journal2006;27:949‐53. ">Heeringa 2006</a>). Furthermore, with an increasing elderly population in most countries, the incidence of AF is set to rise substantially during the coming decades (<a href="./references#CD008980-bbs2-0070" title="WattigneyWA , MensahGA , CroftJB . Increasing trends in hospitalisation for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation2003;108:711‐6. ">Wattigney 2003</a>; <a href="./references#CD008980-bbs2-0059" title="MiyasakiY , BarnesME , GershBJ , ChaSS , BaileyKR , AbhayaratnaWP , et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Circulation2006;114:119‐25. ">Miyasaki 2006</a>; <a href="./references#CD008980-bbs2-0050" title="KrijtheBP , KunstA , BenjaminEJ , LipGY , FrancoOH , HofmanA , et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. European Heart Journal2013;34:2746‐51. ">Krijthe 2013</a>). </p> <p>Individuals with AF have an increased risk of thromboembolic events (e.g. ischaemic stroke, deep venous thrombosis, pulmonary embolism). The mechanisms behind this increased risk are complex and seem to be related to abnormal changes in blood flow, vessel walls and blood constituents that lead to a hypercoagulable or prothrombotic state (<a href="./references#CD008980-bbs2-0069" title="WatsonT , ShantsilaE , LipGYH . Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet2009;373:155‐66. ">Watson 2009</a>). The risk of stroke is about four to five times greater than for people of the same age who are in sinus rhythm, and it is estimated that about 15% to 30% of all strokes are caused by AF (<a href="./references#CD008980-bbs2-0071" title="WolfPA , AbbottRD , KannelWB . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke1991;22:983‐8. ">Wolf 1991</a>; <a href="./references#CD008980-bbs2-0046" title="HenrikssonKM , FarahmandB , AsbergS , EdvardssonN , TerentA . Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. International Journal of Stroke2012;7:276‐81. ">Henriksson 2012</a>). Ischaemic strokes in people with AF are more often disabling and fatal, and generally occur at a higher age compared with strokes in people with a normal sinus rhythm (<a href="./references#CD008980-bbs2-0057" title="MariniC , DeSantisF , SaccoS , RussoT , OlivieriL , TotaroR , et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population study. Stroke2005;36:1115‐9. ">Marini 2005</a>). </p> </section> <section id="CD008980-sec-0032"> <h3 class="title" id="CD008980-sec-0032">Description of the intervention</h3> <p>In people with AF, prevention of thromboembolic events relies mainly on adequate antithrombotic therapy with a vitamin K antagonist (VKA), direct thrombin inhibitor or factor Xa inhibitor (<a href="./references#CD008980-bbs2-0022" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , ClevelandJC , CigarroaJE , et al. Guidelines for the management of patients with atrial fibrillation. Circulation2014; Vol. 129. [DOI: 10.1161/CIR.000000000000000041] ">ACC/AHA/HRS 2014</a>; <a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>). </p> <p>VKAs, such as warfarin, are a class of anticoagulants that reduce blood clotting by inhibiting the action of vitamin K. Treatment with warfarin, with an International Normalised Ratio (INR) target range of 2.0 to 3.0, has been shown to reduce the risk of stroke by about two‐thirds in people with AF and is more effective than antiplatelet agents (<a href="./references#CD008980-bbs2-0044" title="HartRG , PearceLA , AguilarMI . Meta‐analysis: antithrombotic therapy to prevent stroke in patients who have non‐valvular atrial fibrillation. Annals of Internal Medicine2007;146:857‐67. ">Hart 2007</a>). Antithrombotic therapy with a VKA is still recommended as a treatment option in both European and American clinical guidelines for people with AF, who have an increased risk of thromboembolic complications (<a href="./references#CD008980-bbs2-0022" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , ClevelandJC , CigarroaJE , et al. Guidelines for the management of patients with atrial fibrillation. Circulation2014; Vol. 129. [DOI: 10.1161/CIR.000000000000000041] ">ACC/AHA/HRS 2014</a>; <a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>). However, it is estimated that only about 50% to 60% of eligible people with AF actually receive treatment with a VKA, and of those who receive treatment many are treated suboptimally (<a href="./references#CD008980-bbs2-0025" title="BoulangerL , KimJ , FriedmanM , HauchO , FosterT , MenzinJ . Patterns of use of antithrombotic therapy and quality of anticoagulation monitoring among patients with non‐valvular atrial fibrillation in clinical practice. International Journal of Clinical Practice2006;60:258‐64. ">Boulanger 2006</a>; <a href="./references#CD008980-bbs2-0031" title="ConnollySJ , EikelboomJ , O'DonnellM , PogueJ , YusufS . Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation2007;116:449‐55. ">Connolly 2007</a>). One important reason for this is that patients or their physicians fear bleeding complications, especially among the elderly (<a href="./references#CD008980-bbs2-0066" title="SudlowC , RodgersH , KennyRA , ThomsonR . Population‐based study of the use of anticoagulants among patients with atrial fibrillation in the community. BMJ1997;314:1529‐30. ">Sudlow 1997</a>; <a href="./references#CD008980-bbs2-0048" title="HylekEM , Evans‐MolinaC , SheaC , HenaultLE , ReganS . Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation2007;115:2689‐96. ">Hylek 2007</a>). Other reasons are that VKAs exhibit considerable variability in dose response among patients, are subject to multiple food and drug interactions, and have a narrow therapeutic window. Treatment with VKAs thus necessitates frequent laboratory monitoring and dose adjustments, which can be burdensome and difficult in clinical practice. </p> <p>The under‐use of VKAs for stroke prevention in people with AF has prompted the development of other types of anticoagulant drugs. In 2012 a new class of anticoagulants, the factor Xa inhibitors, became available on the market. These factor Xa inhibitors have similar mechanisms of action: binding reversibly to the active site of factor Xa thereby inhibiting the formation of thrombin and fibrin. At least for the orally administered agents, the pharmacokinetic profile appears to be more or less comparable, with a relatively short half‐life leading to once or twice daily dosing of the oral agents (<a href="./references#CD008980-bbs2-0061" title="MousaSA . Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Anticoagulants, Antiplatelets, and Thrombolytics. Springer Science+Business Media, 2010:181‐201. ">Mousa 2010</a>). Factor Xa inhibitors appear to offer practical advantages over VKAs, with fewer food and drug interactions, a fixed daily or even weekly dose, and no need for monitoring of the anticoagulant effect (<a href="./references#CD008980-bbs2-0061" title="MousaSA . Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Anticoagulants, Antiplatelets, and Thrombolytics. Springer Science+Business Media, 2010:181‐201. ">Mousa 2010</a>). There are currently no approved antidotes to counteract the anticoagulation effect of factor Xa inhibitors. </p> <p>Several factor Xa inhibitors (apixaban, rivaroxaban and edoxaban) and one oral direct thrombin inhibitor (dabigatran) have already been compared with VKAs in large, phase III randomised controlled trials (RCTs). Based on the results from these large studies, recently updated guidelines now also recommend such agents as treatment options for preventing stroke and other thromboembolic events in people with AF (<a href="./references#CD008980-bbs2-0035" title="HeidbuchelH , VerhammeP , AlingsM , AntzM , HackeW , OldgrenJ , et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non‐valvular atrial fibrillation. Europace2013;15:625‐51. ">EHRA 2013</a>; <a href="./references#CD008980-bbs2-0022" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , ClevelandJC , CigarroaJE , et al. Guidelines for the management of patients with atrial fibrillation. Circulation2014; Vol. 129. [DOI: 10.1161/CIR.000000000000000041] ">ACC/AHA/HRS 2014</a>; <a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>). </p> </section> <section id="CD008980-sec-0033"> <h3 class="title" id="CD008980-sec-0033">Why it is important to do this review</h3> <p>The prevalence and incidence of AF will most likely continue to increase and will cause more strokes during the coming decades (<a href="./references#CD008980-bbs2-0070" title="WattigneyWA , MensahGA , CroftJB . Increasing trends in hospitalisation for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation2003;108:711‐6. ">Wattigney 2003</a>; <a href="./references#CD008980-bbs2-0059" title="MiyasakiY , BarnesME , GershBJ , ChaSS , BaileyKR , AbhayaratnaWP , et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Circulation2006;114:119‐25. ">Miyasaki 2006</a>; <a href="./references#CD008980-bbs2-0050" title="KrijtheBP , KunstA , BenjaminEJ , LipGY , FrancoOH , HofmanA , et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. European Heart Journal2013;34:2746‐51. ">Krijthe 2013</a>). Factor Xa inhibitors appear to have several pharmacological and practical advantages over VKAs (<a href="./references#CD008980-bbs2-0036" title="EikelboomJW , WeitzJI . New anticoagulants. Circulation2010;121:1523‐32. ">Eikelboom 2010</a>; <a href="./references#CD008980-bbs2-0061" title="MousaSA . Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Anticoagulants, Antiplatelets, and Thrombolytics. Springer Science+Business Media, 2010:181‐201. ">Mousa 2010</a>). They also have the potential to increase the proportion of people with AF who receive effective anticoagulant therapy. Despite the fact that recently updated European and American guidelines now also recommend apixaban, dabigatran, edoxaban and rivaroxaban, many people will continue to be treated with the relatively cheap and effective VKAs in the coming years, although this may vary considerably between countries and regions (<a href="./references#CD008980-bbs2-0035" title="HeidbuchelH , VerhammeP , AlingsM , AntzM , HackeW , OldgrenJ , et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non‐valvular atrial fibrillation. Europace2013;15:625‐51. ">EHRA 2013</a>; <a href="./references#CD008980-bbs2-0022" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , ClevelandJC , CigarroaJE , et al. Guidelines for the management of patients with atrial fibrillation. Circulation2014; Vol. 129. [DOI: 10.1161/CIR.000000000000000041] ">ACC/AHA/HRS 2014</a>; <a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>). A comparison of the efficacy and safety of the factor Xa inhibitors versus VKAs is therefore considered highly relevant. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008980-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008980-sec-0034"></div> <p>To assess the effectiveness and safety of treatment with factor Xa inhibitors versus vitamin K antagonists (VKAs) for preventing cerebral or systemic embolic events in people with AF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008980-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008980-sec-0035"></div> <section id="CD008980-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008980-sec-0037"> <h4 class="title">Types of studies</h4> <p>We sought to identify all unconfounded randomised controlled trials (RCTs) that directly compared the effects of long‐term treatment (more than four weeks) with factor Xa inhibitors with that of VKAs for preventing cerebral and systemic embolism in people with AF. </p> </section> <section id="CD008980-sec-0038"> <h4 class="title">Types of participants</h4> <p>People with AF who were eligible for treatment with anticoagulants in order to reduce the risk of cerebral and systemic embolism. We included people with and without a previous stroke or transient ischaemic attack (TIA). </p> </section> <section id="CD008980-sec-0039"> <h4 class="title">Types of interventions</h4> <p>Treatment with an oral or parenteral factor Xa inhibitor (e.g. antistasin, apixaban, betrixaban, darexaban, DU176b, edoxaban, eribaxaban, fondaparinux, idraparinux, idrabiotaparinux, otamixaban, razaxaban, rivaroxaban, yagin, YM150, LY517717, SSR126517E) versus oral vitamin K antagonists (warfarin and congeners) with the intensity monitored using the International Normalised Ratio (INR). </p> </section> <section id="CD008980-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD008980-sec-0041"> <h5 class="title">Primary outcomes</h5> <p>The composite endpoint of all strokes (both ischaemic and haemorrhagic) and other systemic embolic events. </p> </section> <section id="CD008980-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008980-list-0001"> <li> <p>All strokes (both ischaemic and haemorrhagic)</p> </li> <li> <p>Ischaemic strokes</p> </li> <li> <p>All disabling or fatal strokes (both ischaemic and haemorrhagic). The definition of a disabling stroke depends on the varying criteria in the included studies. Strokes are deemed fatal when death ensues within 30 days of the onset of stroke </p> </li> <li> <p>Systemic embolic events (excluding embolic events in the central nervous system)</p> </li> <li> <p>Major bleedings (defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria or modified ISTH criteria) </p> </li> <li> <p>Intracranial haemorrhages. This includes all intraparenchymal, subdural and epidural haematomas, and subarachnoid haemorrhages confirmed by neuroimaging or post‐mortem examination </p> </li> <li> <p>Non‐major clinically relevant bleedings (defined by ISTH‐criteria or modified ISTH‐criteria)</p> </li> <li> <p>Myocardial infarction. The diagnosis of myocardial infarction was based upon electrocardiographic changes, elevation of enzymes or confirmation during post‐mortem examination </p> </li> <li> <p>Vascular deaths (deaths due to stroke, heart disease, haemorrhage and sudden deaths of unknown cause) </p> </li> <li> <p>All‐cause deaths</p> </li> <li> <p>Other adverse events (i.e. non‐bleeding adverse events)</p> </li> </ul> </p> </section> </section> </section> <section id="CD008980-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialised register' section in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We searched for trials in all languages and arranged translation of relevant papers where required. </p> <section id="CD008980-sec-0044"> <h4 class="title">Electronic searches</h4> <p>We searched the trials registers of the Cochrane Stroke Group and the Cochrane Heart Group (September 2016). In addition, we searched the following electronic databases and trials registers: </p> <p> <ul id="CD008980-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8) in the Cochrane Library (searched August 2017) (<a href="./appendices#CD008980-sec-0132">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Ovid (from 1950 to April 2017) (<a href="./appendices#CD008980-sec-0132">Appendix 2</a>); </p> </li> <li> <p>Embase Ovid (from 1980 to April 2017) (<a href="./appendices#CD008980-sec-0133">Appendix 3</a>); </p> </li> <li> <p>Stroke Trials Directory (<a href="http://www.strokecenter.org/trials" target="_blank">www.strokecenter.org/trials</a>) (June 2012 and September 2016); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched September 2016); </p> </li> <li> <p>ISRCTN Registry Current Controlled Trials (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>) (September 2016); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) (August 2017). </p> </li> </ul> </p> <p>We developed the initial MEDLINE and Embase search strategies with the help of the Cochrane Stroke Group Information Specialist (2013) and updated search strategies with help from a librarian at the Norwegian Institute of Public Health (2016). We adapted the MEDLINE strategy for the searches of the other databases listed above. </p> </section> <section id="CD008980-sec-0045"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify further published, unpublished, ongoing and planned trials we: </p> <p> <ul id="CD008980-list-0003"> <li> <p>screened reference lists of relevant trials;</p> </li> </ul> <ul id="CD008980-list-0004"> <li> <p>contacted the following relevant pharmaceutical companies:</p> <ul id="CD008980-list-0005"> <li> <p>Sanofi (July 2012), responded and additional data were received for <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; </p> </li> <li> <p>Bristol Myers Squibb (July 2012), no response;</p> </li> <li> <p>Daiichi Sankyo (July 2012), no response;</p> </li> <li> <p>Portola Pharmaceuticals (July 2012), no response;</p> </li> <li> <p>Bayer (July 2012), no response;</p> </li> <li> <p>Astellas Europe (July 2012), no response;</p> </li> </ul> </li> <li> <p>contacted the following authors, colleagues and researchers active in the field:</p> <ul id="CD008980-list-0006"> <li> <p>HR Büller (June and July 2012), responded, additional data subsequently provided by sponsor of <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a> (Sanofi Aventis); </p> </li> <li> <p>CB Granger (June and July 2012), responded, but no additional data provided for <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; </p> </li> <li> <p>S Ogawa (June and July 2012), no response and no additional data provided for <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; </p> </li> <li> <p>N Chung (June and July 2012), no response and no additional data provided for <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; </p> </li> <li> <p>JI Weitz (June and July 2012), responded, but no additional data provided for <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; </p> </li> <li> <p>MD Ezekowitz (June and July 2012), responded, but no additional data provided for <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>; </p> </li> <li> <p>M Hori (June and July 2012), responded, additional data were provided for <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; </p> </li> <li> <p>M Patel (June and July 2012), no response and no additional data provided for <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; </p> </li> <li> <p>AGG Turpie (June and July 2012), no response and no additional data provided for <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; </p> </li> <li> <p>GYH Lip (June and July 2012), no response and no additional data provided for <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; </p> </li> </ul> </li> <li> <p>searched Google Scholar (<a href="http://scholar.google.co.uk/" target="_blank">http://scholar.google.co.uk/</a>) (latest search September 2016); </p> </li> </ul> <ul id="CD008980-list-0007"> <li> <p>used Science Citation Index Cited Reference search for forward tracking of relevant references; </p> </li> </ul> <ul id="CD008980-list-0008"> <li> <p>used clinical outcome data from apixaban, rivaroxaban and edoxaban published in publicly available reports published on the website of the Food and Drug Administration (FDA); </p> </li> </ul> <ul id="CD008980-list-0009"> <li> <p>contacted the European Medicines Agency (EMA) to gain access to the clinical trials study reports that were submitted by pharmaceutical companies for the marketing authorisation approval procedures of apixaban, rivaroxaban and edoxaban. Access to clinical study data of these compounds was granted by the EMA in 2015 and relevant outcome data have been included in this update. </p> </li> </ul> </p> </section> </section> <section id="CD008980-sec-0046"> <h3 class="title" id="CD008980-sec-0046">Data collection and analysis</h3> <section id="CD008980-sec-0047"> <h4 class="title">Selection of studies</h4> <p>One of the review authors (KBS) independently screened titles and abstracts of references identified by the searches and excluded obviously irrelevant citations. We obtained the full paper copies of the remaining articles, and both authors assessed these for inclusion. We resolved any uncertainties or disagreements on whether papers were eligible for inclusion by discussion with external experts. If we excluded a trial we kept a record of both the report and the reason for exclusion. </p> <p>We did not use a scoring system to assess the quality of each trial, but for each included trial we collected information about: </p> <p> <ul id="CD008980-list-0010"> <li> <p>the method of randomisation (including concealment of allocation);</p> </li> <li> <p>blinding (care provider, patient, outcome assessment);</p> </li> <li> <p>the number of participants lost to follow‐up;</p> </li> <li> <p>whether or not the trial data were analysed according to the 'intention‐to‐treat' principle. </p> </li> </ul> </p> </section> <section id="CD008980-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>Both review authors independently extracted data from the report of each eligible trial and recorded the information on a specially designed data extraction form. We were not blinded to journal or institution and extracted the following data from each report: </p> <p> <ul id="CD008980-list-0011"> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>method of randomisation;</p> </li> <li> <p>masked versus open‐label intervention;</p> </li> <li> <p>diagnostic criteria used for the assessment of major vascular events, stroke (both ischaemic and haemorrhagic), vascular death (including fatal haemorrhages), myocardial infarction or systemic embolism; </p> </li> <li> <p>number of participants in each treatment group with outcome events;</p> </li> <li> <p>generic name and dose(s) of factor Xa inhibitor used;</p> </li> <li> <p>duration of anticoagulant therapy in the trial, the intensity of anticoagulation dose‐adjusted using INR, and adherence to anticoagulant treatment; </p> </li> <li> <p>concomitant treatment with other anticoagulants, antiplatelets, or both, or any non‐steroidal anti‐inflammatory drugs; </p> </li> <li> <p>outcomes (as listed above).</p> </li> </ul> </p> <p>One review author (KBS) entered the data into the Cochrane Review Manager software, Review Manager 5 (<a href="./references#CD008980-bbs2-0064" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). The other review author (EB) checked these data against the hard‐copy data extraction forms to correct any clerical data entry errors. If any relevant data were missing from the available publications, we directly contacted the principal investigators or sponsor concerned, or used data from clinical study reports submitted to the EMA or FDA, or both. </p> </section> <section id="CD008980-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used Cochrane's recommended tool for assessing the risk of bias in included studies (<a href="./references#CD008980-bbs2-0030" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Cochrane Handbook 2011</a>). Both review authors scored the potential for bias of specific features of each study as 'low', 'unclear' or 'high' risk. We resolved any disagreements by discussion with external experts. </p> </section> <section id="CD008980-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated a weighted estimate of the treatment effects across trials (odds ratio, OR). </p> </section> <section id="CD008980-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>In cases where the published information did not allow for an intention‐to‐treat analysis, we contacted the authors to get as complete follow‐up data as possible on all randomised participants for the originally proposed period of follow‐up, or used data from clinical study reports submitted to the European Medicines Agency (EMA) and Food and Drug Administration (FDA). </p> </section> <section id="CD008980-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested for heterogeneity between trial results with the Cochrane Q statistic and I<sup>2</sup> statistic (percentage of total variation across studies due to heterogeneity). We interpreted the amount of heterogeneity as 'low', 'moderate' and 'high' for I<sup>2</sup> cut‐off values of 25%, 50% and 75%, respectively. We also assessed heterogeneity qualitatively. </p> </section> <section id="CD008980-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to assess reporting bias. We also assessed these plots qualitatively.</p> </section> <section id="CD008980-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We calculated a weighted estimate of the typical treatment effect across trials using OR, by means of a fixed‐effect model. However, in case of moderate to high heterogeneity of treatment effects, we used a random‐effects model to enable further comparison of the overall treatment effects. </p> </section> <section id="CD008980-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed pre‐planned subgroup analyses for:</p> <p> <ul id="CD008980-list-0012"> <li> <p>type of factor Xa inhibitor;</p> </li> <li> <p>dose of factor Xa inhibitor;</p> </li> <li> <p>route of administration of factor Xa inhibitor;</p> </li> <li> <p>previous stroke versus no previous stroke;</p> </li> <li> <p>participants who received VKA treatment with time‐in‐therapeutic range (TTR) equal to or greater than 60% ("high" quality) versus less than 60% ("low" quality) (<a href="./references#CD008980-bbs2-0032" title="ConnollySJ , PogueJ , EikelboomJ , FlakerG , CommerfordP , FranzosiG , the ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of International Normalized Ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation2008;118:2029‐37. ">Connolly 2008</a>; <a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>); </p> </li> <li> <p>VKA treatment‐experienced participants versus treatment‐naive participants;</p> </li> <li> <p>participants who received concomitant antiplatelet therapy (aspirin) versus those who did not; </p> </li> <li> <p>age less than 75 years versus age 75 years or over;</p> </li> <li> <p>race;</p> </li> <li> <p>sex;</p> </li> <li> <p>baseline stroke risk factors (assessed by the <a href="./references#CD008980-bbs2-0029" title="GageBF , WatermanAD , ShannonW , BoechlerM , RichMW , RadfordMJ . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA2001;285(22):2864‐70. ">CHADS2</a> score). </p> </li> </ul> </p> <p>We used the method described by Deeks for performing subgroup analyses (<a href="./references#CD008980-bbs2-0033" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care. Meta‐analysis in Context. London: BMJ Books, 2001:285‐312. ">Deeks 2001</a>). </p> </section> <section id="CD008980-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>In the case of any evidence of heterogeneity that could not be explained by study quality, we conducted a sensitivity analysis excluding any open‐label trials. </p> <section id="CD008980-sec-0057"> <h5 class="title">GRADE and 'Summary of findings'</h5> <p>We assessed the quality of evidence by using the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias). Overall quality of the evidence was assessed as either high, moderate, low or very low (<a href="./references#CD008980-bbs2-0047" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We also included a <a href="./full#CD008980-tbl-0001">summary of findings Table for the main comparison</a>, comparing factor Xa inhibitors with vitamin K antagonists for the important outcomes of: </p> <p> <ul id="CD008980-list-0013"> <li> <p>stroke and other systemic embolic events;</p> </li> <li> <p>all strokes;</p> </li> <li> <p>major bleedings;</p> </li> <li> <p>intracranial haemorrhages;</p> </li> <li> <p>all‐cause death.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008980-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008980-sec-0058"></div> <section id="CD008980-sec-0059"> <h3 class="title">Description of studies</h3> <p>For detailed descriptions see the <a href="./references#CD008980-sec-0154" title="">Characteristics of included studies</a> and <a href="./references#CD008980-sec-0155" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD008980-sec-0060"> <h4 class="title">Results of the search</h4> <p>The literature search identified a total of 1900 reports (updated search April 2017; see <a href="#CD008980-fig-0001">Figure 1</a> for further details). After removing duplicates and screening titles and abstracts, we identified 21 reports that we retrieved in full text and evaluated for eligibility. </p> <div class="figure" id="CD008980-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008980-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Eight of the 21 reports were either: overviews or expert reviews that contained no new outcome data; publications of study protocols; studies with no direct comparison of the study drug to vitamin K antagonists (VKAs); or studies with a duration shorter than four weeks (see <a href="./references#CD008980-sec-0155" title="">Characteristics of excluded studies</a> for further details). </p> <p>We included the remaining 13 reports, which were original publications of randomised controlled trials (RCTs) enrolling a total of 67,688 participants with atrial fibrillation (AF) who were considered eligible for long‐term (more than four weeks) anticoagulation treatment with a VKA (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). </p> <p>In <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a> 97 participants recruited by a single centre were excluded from the intention‐to‐treat analyses; the reason for this was not clearly stated in the publication. In <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a> 93 participants, all recruited by one centre, were excluded from the intention‐to‐treat analyses because of good clinical practice (GCP) violations that rendered the data unreliable. After excluding these 190 participants, we had data from 67,498 participants for further analysis. </p> <p>The included studies directly compared various types of factor Xa inhibitors with VKAs. One trial studied the compound idraparinux, which was administered subcutaneously once weekly (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>). One trial studied idrabiotaparinux—a biotin moiety to idraparinux—that was also administered subcutaneously once weekly (<a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>) . The remaining trials all studied oral factor Xa inhibitors (i.e. apixaban, betrixaban, darexaban, edoxaban and rivaroxaban), that were administered once or twice daily. </p> <p>All studies randomised participants to more than one dose of the studied factor Xa inhibitor. Studies of the compounds apixaban (<a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>), rivaroxaban (<a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>) and edoxaban (<a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>) contributed to approximately 90% of all data included in this review. </p> <p>Dose‐adjusted warfarin was the active comparator in all included trials. In most trials the target INR for warfarin treatment was between 2.0 and 3.0. In <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>, participants aged 70 years and over had a target INR of 2.0 to 2.6, whereas in <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>, <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a> and <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>, participants in this age category had a target INR of 1.6 to 2.6. The quality of the anticoagulation with warfarin (time in therapeutic range (TTR) calculated using the Rosendaal method) was reported in 11 trials (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). Reported (median) TTR values ranged from 45% to 83% in these studies. TTR values were not reported in two studies (<a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>). </p> <p>The mean baseline CHADS<sub>2</sub> score in the included studies ranged from 1.9 to 3.5. Mean baseline CHADS<sub>2</sub> scores were not reported in four studies (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). </p> <p>All participants were aged 18 years or older. Mean and median ages of randomised participants ranged between 65 and 74 years, and approximately one‐third of all randomised participants were women. Mean ages and gender were not stated in one study (<a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>). </p> <p>The median duration of follow‐up ranged from 12 weeks to 2.8 years. Six trials (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>) were all designed as event‐driven studies, whereas the remaining smaller studies all had predefined durations of follow‐up. </p> <p>The included studies used different definitions of 'disabling stroke'. One study used the modified Rankin scale to score stroke outcome; scores from 0 to 2 were defined as 'non‐disabling', and scores from 3 to 5 as 'disabling' (<a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>). The outcome of stroke was only assessed by the investigator in this study. Data on disabling strokes (defined as 'strokes with serious residual disability') were also reported in <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>, though it was not stated which functional outcome scale and which cut‐off value, if any, were used to define 'serious residual disability'. In one study it was unclear which scale was used for assessing functional outcome in one participant who suffered an ischaemic stroke during the study period (<a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>). It was, however, stated that this stroke was 'resolved' and we have therefore chosen not to count this as a disabling stroke. </p> </section> </section> <section id="CD008980-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>For detailed information see: <a href="./references#CD008980-sec-0154" title="">Characteristics of included studies</a>, <a href="#CD008980-fig-0002">Figure 2</a> ('Risk of bias' graph) and <a href="#CD008980-fig-0003">Figure 3</a> ('Risk of bias' summary). </p> <div class="figure" id="CD008980-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD008980-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008980-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD008980-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD008980-sec-0062"> <h4 class="title">Allocation</h4> <p>All 13 included trials randomly assigned participants to treatment groups, using either a computerised interactive voice response system (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>), block randomisation schedule (<a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>), or a non‐specified randomisation method (<a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>). </p> <p>In six studies, randomisation was stratified for previous warfarin use (warfarin experienced versus warfarin naive) or clinical site, or both, (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). One study stratified participants according to their baseline CHADS<sub>2</sub> score (scores 2 to 3 versus 4 to 6) and need for a reduction in the edoxaban dose (30 mg versus 60 mg) (<a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>). The remaining trials did not report stratification for any baseline variables. </p> </section> <section id="CD008980-sec-0063"> <h4 class="title">Blinding</h4> <p>Six studies were fully double‐masked (blinded) trials (<a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>): we judged these studies as having low risk of performance bias. Another six studies were partially‐masked trials, i.e. the different doses of factor Xa inhibitors were administered in a double‐masked fashion, but warfarin was administered open‐label (<a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>): these studies were judged as having unclear or high risk of performance bias. We included only one fully open‐label study with a high risk of performance bias (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>). </p> <p>Adjudication of outcome events was performed by blinded, centralised committees in 11 studies (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). A centralised adjudication committee was also used in <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>, but it was unclear whether this committee was blinded or not, since this was not specified in the publication. No details on the adjudication of outcome events were provided for <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>. </p> </section> <section id="CD008980-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>The reported analysis for efficacy outcomes was a (modified) intention‐to‐treat analysis in 10 studies (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). In one study the primary efficacy outcome (composite of stroke and systemic embolic events) was reported for the intention‐to‐treat population; other efficacy outcomes were analysed in the per protocol population, defined as participants without any major study protocol violations (<a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>). This definition led to the exclusion of 6/1280 randomised participants (0.5%) from all secondary efficacy analyses in <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>. Two studies only analysed efficacy outcomes in the 'safety population', defined as participants who received at least one dose of the study drug and had at least one post‐dose assessment (<a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>). This led to the exclusion of 1/235 participants (0.4%) in <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>, and 3/1146 (0.3%) participants in <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>. </p> <p>Four studies analysed safety outcomes in the intention‐to‐treat population (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>; <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>; <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>; <a href="./references#CD008980-bbs2-0009" title="ConnolySJ , EikelboomJ , DorianP , HohnloserSH , GretlerDD , SinhaU , et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose‐ranging study (Explore‐Xa). European Heart Journal2013;34(20):1498‐505. [DOI: 10.1093/eurheartj/eht/039] ">EXPLORE‐Xa 2013</a>). Nine studies only analysed safety outcomes in the 'safety population', defined as the participants who received at least one dose of the study drug (<a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>; <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). This led to the exclusion of one (0.4%); three (0.3%); 61 (0.3%); five (2.3%); 28 (0.2%); two (0.2%); 11 (2.1%) and 79 (0.4%) participants in <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>, <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>, <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>, <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>, <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>, <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>, <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a> and <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>, respectively. </p> <p>We used data from a subgroup analysis in people with previous stroke and TIA who were randomised into the ROCKET AF trial (<a href="./references#CD008980-bbs2-0043" title="HankeyGJ , PatelMR , StevensSR , BeckerRC , BreithardtG , CaroleiA . Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology2012;11:315‐22. ">Hankey 2012</a>). </p> <p>Loss to follow‐up in the included studies was generally low, ranging from 0% (<a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>) to 2.7% (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>) of all randomised participants. The number of participants lost to follow‐up was not reported in <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>. </p> </section> <section id="CD008980-sec-0065"> <h4 class="title">Selective reporting</h4> <p>There was no indication of selective reporting in any of the included studies. All predefined efficacy and safety outcomes stated in the study protocols were reported in the publications, abstracts or clinical study reports submitted to regulatory authorities. </p> </section> <section id="CD008980-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>One study was terminated prematurely after a recommendation from the trial's Data and Safety Monitoring Board because of excess bleeding complications in the idraparinux group (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>). Another study was also halted prematurely by the sponsor (Sanofi Aventis), but for commercial or strategic reasons (<a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>). None of the other included trials were stopped prematurely. </p> <p>Enrolment into the treatment arm receiving darexaban 240 mg once daily (<a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>) and the arm receiving edoxaban 60 mg twice daily (<a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>) was halted after recommendations by the trials' respective Data and Safety Monitoring Boards due to an excess of bleeding complications. </p> </section> </section> <section id="CD008980-sec-0067"> <h3 class="title" id="CD008980-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD008980-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>Although we included 13 studies in this review, most of the following analyses include data from less than 13 studies. </p> <section id="CD008980-sec-0068"> <h4 class="title">Primary outcome</h4> <section id="CD008980-sec-0069"> <h5 class="title">Composite endpoint of all strokes (both ischaemic and haemorrhagic) and other systemic embolic events </h5> <p>This outcome was reported in all 13 included studies (number of participants (n) = 67,477). Most data (approximately 90%) came from studies that used the agents apixaban (<a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0003" title="OgawaS , ShinoharaY , KanmuriK . Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2011;75:1852‐9. ">ARISTOTLE‐J 2011</a>), rivaroxaban (<a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>) and edoxaban (<a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>; <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>; <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>). Treatment with a factor Xa inhibitor significantly decreased the number of strokes and other systemic embolic events compared with dose‐adjusted warfarin in participants with atrial fibrillation (AF) (odds ratio (OR) 0.89, 95% confidence interval (CI) 0.82 to 0.97; 13 studies; 67,477 participants; high‐quality evidence: <a href="./references#CD008980-fig-0004" title="">Analysis 1.1</a>). We observed low, non‐statistically significant heterogeneity (I<sup>2</sup> = 13%). The total number of non‐central nervous system systemic embolic events was very low, contributing to approximately 5% of the total outcomes of the composite endpoint, meaning that the primary outcome was largely driven by the stroke component (ischaemic and haemorrhagic strokes). </p> <p>We calculated the number needed to treat (NNT), or number need to treat for an additional harmful outcome (NNTH), for studies with median follow‐up periods of one year or more (<a href="http://archie.cochrane.org/sections/documents/view?version=z1307221314505956570231682179101%26format=REVMAN#STD-ARISTOTLE-2011" target="_blank">ARISTOTLE 2011</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1307221314505956570231682179101%26format=REVMAN#STD-ROCKET-AF-2011" target="_blank">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>). We used a web‐based NNT calculator to calculate the NNTs/NNTHs with 95% CIs (<a href="http://graphpad.com/quickcalcs/NNT2" target="_blank">graphpad.com/quickcalcs/NNT2</a>) and entered the outcome data used in <a href="./references#CD008980-fig-0004" title="">Analysis 1.1</a>. The NNT for apixaban was 169 (95% CI 94.5 to 772.7) for a median treatment/follow‐up period of 1.8 years (<a href="http://archie.cochrane.org/sections/documents/view?version=z1307221314505956570231682179101%26format=REVMAN#STD-ARISTOTLE-2011" target="_blank">ARISTOTLE 2011</a>). Assuming that the risk of these outcome events was constant during treatment, this translates into a NNT of 304 for one year of treatment. This NNT indicates that 304 people need to be treated with apixaban for one year in order to prevent one stroke or systemic embolic event compared with warfarin. For rivaroxaban the NNT was 194 for a median treatment/follow‐up period of 1.9 years, which translates into a NNT of 376 per year. Because the 95% CI for the absolute risk reduction (0.52%) extends from a negative number (‐0.13%) to a positive number (1.17%), it is difficult to compute a 95% CI for the NNT in this case. </p> <p>We could only calculate a NNTH for edoxaban, since the OR was greater than 1 in <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a> (OR 1.01, 95% CI 0.88 to 1.15). The NNTH was 2736 for a median treatment/follow‐up period of 2.8 years, which is equivalent to a NNTH of 7661 per year. This NNTH indicates that 7661 people need to be treated for one year with edoxaban to cause one more stroke or systemic embolic embolism compared with warfarin. </p> </section> </section> <section id="CD008980-sec-0070"> <h4 class="title">Secondary outcomes</h4> <section id="CD008980-sec-0071"> <h5 class="title">All strokes (ischaemic and haemorrhagic)</h5> <p>The composite endpoint of 'all strokes' was reported in all 13 included studies (n = 67,449). Treatment with a factor Xa inhibitor significantly decreased the number of strokes compared with warfarin (OR 0.89, 95% CI 0.81 to 0.97; 13 studies; 67,449 participants; high‐quality evidence: <a href="./references#CD008980-fig-0005" title="">Analysis 1.2</a>). There was low, non‐statistically significant heterogeneity (I<sup>2</sup> = 18%). </p> </section> <section id="CD008980-sec-0072"> <h5 class="title">Ischaemic stroke</h5> <p>We were able to calculate the effect of study versus control treatment on the number of ischaemic strokes for 12 studies (n = 66,306). No data were available for <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>. The analysis showed no statistically significant decrease or increase in the number of ischaemic strokes in participants treated with a factor Xa inhibitor compared with warfarin (OR 1.03, 95% CI 0.92 to 1.14: <a href="./references#CD008980-fig-0006" title="">Analysis 1.3</a>). There was moderate, non‐statistically significant heterogeneity between the analysed studies (I<sup>2</sup> = 37%). </p> </section> <section id="CD008980-sec-0073"> <h5 class="title">Disabling or fatal strokes</h5> <p>Seven studies that included 39,026 participants reported data on disabling or fatal strokes. Treatment with a factor Xa inhibitor was not associated with a statistically significant reduction in the number of disabling or fatal strokes compared with warfarin (OR 0.91, 95% CI 0.77 to 1.06: <a href="./references#CD008980-fig-0007" title="">Analysis 1.4</a>). We observed low, non‐statistically significant heterogeneity (I<sup>2</sup> = 16%). </p> </section> <section id="CD008980-sec-0074"> <h5 class="title">Non‐central nervous system (CNS) systemic embolic events</h5> <p>The occurrence of non‐CNS systemic embolic events was reported in all 13 included studies (n = 67,449). Treatment with a factor Xa inhibitor significantly reduced the number of non‐CNS systemic embolic events compared with warfarin (OR 0.68, 95% CI 0.48 to 0.96: <a href="./references#CD008980-fig-0008" title="">Analysis 1.5</a>). There was low, non‐statistically significant heterogeneity (I<sup>2</sup> = 15%). </p> </section> <section id="CD008980-sec-0075"> <h5 class="title">Major bleedings</h5> <p>All 13 included studies (n = 67,396) reported the number of major bleedings defined either by the ISTH‐criteria, or a slight modification of these criteria. Treatment with a factor Xa inhibitor significantly reduced the number of major bleedings compared with warfarin (OR 0.78, 95% CI 0.73 to 0.84; moderate‐quality evidence: <a href="./references#CD008980-fig-0009" title="">Analysis 1.6</a>). There was, however, high and statistically significant heterogeneity (I<sup>2</sup> = 83%). Because of this, we performed an analysis using a random‐effects model. Contrary to the results from the fixed‐effect model, this analysis did not show a statistically significant decrease in the number of major bleedings in people treated with factor Xa inhibitors compared with warfarin (OR 0.88, 95% CI 0.66 to 1.17). </p> <p>To further explore the observed statistical heterogeneity we also performed a pre‐specified sensitivity analysis in which we excluded open‐label studies (sensitivity analyses not shown in forest plots). The only included open‐label trial was <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>, which was stopped prematurely due to an excess of major bleeding in the idraparinux arm (OR 2.62, 95% CI 1.70 to 4.03). The sensitivity analysis excluding <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>, using a fixed‐effect model, showed that treatment with a factor Xa inhibitor significantly reduced the number of major bleedings compared with warfarin (OR 0.75, 95% CI 0.69 to 0.81). However, we still observed moderate and statistically significant heterogeneity (I<sup>2</sup> = 72%). A sensitivity analysis excluding <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>, but using a random‐effects model, also showed a statistically significant decrease in the number of major bleedings in people treated with factor Xa inhibitors (OR 0.76, 95% CI 0.60 to 0.96). </p> </section> <section id="CD008980-sec-0076"> <h5 class="title">Intracranial haemorrhages (ICHs)</h5> <p>Data on ICHs were reported in 12 studies that randomised 66,259 participants. No data were reported for <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>. Treatment with a factor Xa inhibitor significantly reduced the risk of ICH compared with warfarin (OR 0.50, 95% CI 0.42 to 0.59; 12 studies; 66,259 participants; high‐quality evidence: <a href="./references#CD008980-fig-0010" title="">Analysis 1.7</a>). We observed statistically significant, moderate heterogeneity (I<sup>2</sup> = 55%). An analysis using a random‐effects model also indicated a statistically significant reduction of ICHs in participants treated with a factor Xa inhibitor compared with warfarin (OR 0.57, 95% CI 0.40 to 0.82). </p> <p>We performed a pre‐specified sensitivity analysis in which we excluded open‐label studies to further explore the observed moderate heterogeneity (sensitivity analyses not shown in forest plots). As mentioned previously, the only open‐label study was the prematurely halted <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>, in which a statistically significant increase in the risk of ICHs was observed (OR 11.10, 95% CI 1.43 to 86.02). The sensitivity analysis with a fixed‐effect model showed that treatment with a factor Xa inhibitor significantly reduced the number of ICHs compared with warfarin (OR 0.47, 95% CI 0.40 to 0.56). We observed low, non‐statistically significant heterogeneity in this analysis (I<sup>2</sup> = 27%). </p> </section> <section id="CD008980-sec-0077"> <h5 class="title">Non‐major clinically relevant bleedings</h5> <p>All 13 studies reported the number of non‐major clinically relevant bleeding defined by either ISTH criteria or a modification of these criteria. Data on 67,396 randomised participants were available for analysis. We found a statistically significant difference in the number of non‐major clinically relevant bleedings, which favoured factor Xa inhibitors over warfarin (OR 0.86, 95% CI 0.82 to 0.91: <a href="./references#CD008980-fig-0011" title="">Analysis 1.8</a>). We observed statistically significant and high heterogeneity (I<sup>2</sup> = 88%). An analysis with a random‐effects model showed no statistically significant difference in the number of non‐major clinically relevant bleedings that were observed in the two treatment groups (OR 0.87, 95% CI 0.70 to 1.07). </p> <p>We performed a pre‐specified sensitivity analysis in which we excluded open‐label studies (sensitivity analysis not shown in forest plots). This sensitivity analysis again excluded the prematurely halted <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a> study, in which a statistically significant increase in the risk of non‐major clinically relevant bleedings was reported (OR 1.48, 95% CI 1.23 to 1.79). This analysis, using a fixed‐effect model, showed that treatment with factor Xa inhibitors did significantly reduce the number of non‐major clinically relevant bleedings compared with warfarin (OR 0.83, 95% CI 0.79 to 0.87). However, we observed statistically significant, high heterogeneity (I<sup>2</sup> = 84%). We repeated the same sensitivity analysis using a random‐effects model, and found similar results (OR 0.80, 95% CI 0.65 to 0.98). </p> </section> <section id="CD008980-sec-0078"> <h5 class="title">Myocardial infarction</h5> <p>The number of myocardial infarctions that occurred during the study period was reported in 10 studies that randomised 62,703 participants. No data were available for <a href="./references#CD008980-bbs2-0012" title="LipGYH , HalperinJL , PetersenP , RodgerGM , RenfurmRW . Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non‐valvular atrial fibrillation: a dose confirmation study (OPAL‐2). Journal of Thrombosis and Haemostatis2011;9 Suppl 2:748. ">OPAL‐2 2011</a>, <a href="./references#CD008980-bbs2-0006" title="YamashitaT , KoretsuneY , YasakaM , InoueH , KawaiY , YamaguchiT , et al. Randomized, multicenter, warfarin‐controlled phase II study of edoxaban in Japanese patients with non‐valvular atrial fibrillation. Circulation Journal2012;76:1840‐7. ">Edoxaban Japan 2012</a> and <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>. There was no statistically significant difference between the number of myocardial infarctions in participants treated with factor Xa inhibitors compared with warfarin (OR 0.96, 95% CI 0.84 to 1.10: <a href="./references#CD008980-fig-0012" title="">Analysis 1.9</a>). We observed no heterogeneity in the analysis (I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0079"> <h5 class="title">Vascular deaths</h5> <p>Vascular deaths were reported in 10 studies (n = 45,027). No data were available for <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a>, <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a> and <a href="./references#CD008980-bbs2-0004" title="BullerHR , HalperinJ , HankeyGJ , PillionG , PrinsMH , RaskobGE . Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis2014;12(6):824‐30. ">BOREALIS AF STUDY 2014</a>. The analysis showed a statistically significant difference between the number of vascular deaths, which favoured factor Xa inhibitors over warfarin (OR 0.86, 95% CI 0.79 to 0.94: <a href="./references#CD008980-fig-0013" title="">Analysis 1.10</a>). There was no sign of any heterogeneity between the included studies (I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0080"> <h5 class="title">All‐cause deaths</h5> <p>The number of participants who died from any cause was reported in 10 studies (n = 65,624). No data were available for <a href="./references#CD008980-bbs2-0007" title="WeitzJI , ConnollySJ , PatelI , SalazarD , RohatagiS , MendellJ , et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104:633‐41. ">Edoxaban US/Europe 2010</a>, <a href="./references#CD008980-bbs2-0011" title="TurpieAGGF , LipGYH , MinematsuK , GotoS , RenfurmRW , WongKSL . Safety and tolerability of YM150 in subjects with non‐valvular atrial fibrillation: a phase II study. European Heart Journal2010;31 Suppl 1:173. ">OPAL‐1 2010</a> and <a href="./references#CD008980-bbs2-0005" title="ChungN , JeonHK , LienLM , LaiWT , TseHF , ChungWS , et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non‐valvular atrial fibrillation. Thrombosis and Haemostasis2011;105:535‐45. ">Edoxaban Asia 2011</a>. Treatment with a factor Xa inhibitor significantly reduced the number of deaths compared with warfarin (OR 0.89, 95% 0.83 to 0.95; 10 studies; 65,624 participants; moderate‐quality evidence: <a href="./references#CD008980-fig-0014" title="">Analysis 1.11</a>). We observed no heterogeneity (I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0081"> <h5 class="title">Other adverse events</h5> <p>We did not analyse this outcome because of a paucity of data on adverse events other than the ones reported above. Sufficient data on other adverse events were only systematically presented for the large phase III studies of apixaban, rivaroxaban and edoxaban (<a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>, <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>) and are listed in the appendices of the original publications, in the clinical study reports of these three compounds that were submitted to regulatory authorities, and in the approved product labels. Of note, there was no evidence for an increased risk of hepatotoxicity associated with apixaban, rivaroxaban or edoxaban compared with warfarin based on these data. </p> </section> </section> <section id="CD008980-sec-0082"> <h4 class="title">Subgroup analyses</h4> <p>We performed 22 pre‐specified subgroup analyses for the primary efficacy outcome (composite of stroke and systemic embolic events) and safety outcome (major bleedings). Results of these subgroup analyses are presented below. </p> <p>Interpretation of subgroup data requires caution because the trials were not powered to detect differences in these subgroups. Furthermore, randomisation into the included studies was in most cases not stratified by the factors that were analysed in these subgroup analyses; it is therefore not possible to ensure that potential confounders were balanced across treatment arms. </p> <section id="CD008980-sec-0083"> <h5 class="title">Different factor Xa inhibitors</h5> <section id="CD008980-sec-0084"> <h6 class="title">Subgroup analysis 1: stroke and systemic embolic events</h6> <p>An analysis of the different factor Xa inhibitors showed that only the agents apixaban (OR 0.78, 95% CI 0.65 to 0.93) and rivaroxaban (OR 0.85, 95% CI 0.72 to 1.00) significantly decreased the number of strokes and systemic embolic events compared with warfarin (<a href="./references#CD008980-fig-0004" title="">Analysis 1.1</a>). The agents idraparinux, idrabiotaparinux, edoxaban, darexaban and betrixaban did not show a statistically significant difference, but there was no evidence of any statistically significant differences between the risk estimates of these agents and those of apixaban or rivaroxaban (test for subgroup differences: P = 0.36; I<sup>2</sup> = 10%). </p> </section> <section id="CD008980-sec-0085"> <h6 class="title">Subgroup analysis 2: major bleedings</h6> <p>. Major bleedings occurred significantly less often in participants that were treated with apixaban (OR 0.69, 95% CI 0.60 to 0.80), betrixaban (OR 0.19, 95% CI 0.05 to 0.82) and edoxaban (OR 0.63, 95% CI 0.56, 0.71) compared with warfarin (<a href="./references#CD008980-fig-0009" title="">Analysis 1.6</a>). More major bleedings were observed in participants treated with idraparinux compared with warfarin (OR 2.62, 95% CI 1.70 to 4.03). We observed no statistically significant differences for idrabiotaparinux, rivaroxaban and darexaban compared with warfarin. There was evidence of high heterogeneity and statistically significant differences between the risk estimates of the various agents (test for subgroup differences: P &lt; 0.00001; I<sup>2</sup> = 95%). </p> </section> </section> <section id="CD008980-sec-0086"> <h5 class="title">Different doses of factor Xa inhibitors</h5> <section id="CD008980-sec-0087"> <h6 class="title">Subgroup analysis 3: stroke and systemic embolic events</h6> <p>A total of 22 different doses of the included factor Xa inhibitors were assessed in the studies (<a href="./references#CD008980-fig-0017" title="">Analysis 3.1</a>). Unfortunately, we could not use data from <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>, since the number of events were not reported for the different dose levels used in this study. Overall, we observed no statistically significant differences in the number of stroke or systemic embolic events between the various tested doses of the factor Xa inhibitors compared with warfarin (test for subgroup differences: P = 0.22; I<sup>2</sup> = 19.1%). Both apixaban doses (2.5 mg and 5 mg twice daily) and the rivaroxaban dose (15 mg once‐daily) showed a statistically significant decreased number of strokes and other systemic embolic events compared with warfarin. Differences in thromboembolic events between the other doses and types of factor Xa inhibitors compared with warfarin were not statistically significant. </p> </section> <section id="CD008980-sec-0088"> <h6 class="title">Subgroup analysis 4: major bleedings</h6> <p>We could use data about 21 different doses of factor Xa inhibitors for this subgroup analysis (<a href="./references#CD008980-fig-0018" title="">Analysis 3.2</a>). Outcome data for the two different idraparinux doses were pooled because we could not obtain data for two separate doses that were used in <a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>. Overall, we observed statistically significant differences in the number of major bleedings between the doses of factor Xa inhibitors compared with warfarin (test for subgroup differences: P &lt; 0.00001; I<sup>2</sup> = 78%). For both idraparinux doses and the edoxaban dose of 60 mg twice daily, there was a statistically significant increase in the number of major bleedings compared with warfarin. We observed a statistically significant decrease in the number of major bleedings compared with warfarin for two doses of edoxaban (30 mg and 60 mg once daily) and for apixaban (5 mg twice‐daily dose). </p> </section> </section> <section id="CD008980-sec-0089"> <h5 class="title">Route of administration</h5> <section id="CD008980-sec-0090"> <h6 class="title">Subgroup analysis 5: stroke and systemic embolic events</h6> <p>We compared the number of stroke and systemic embolic events in people treated with oral versus parenteral factor Xa inhibitors (<a href="./references#CD008980-fig-0015" title="">Analysis 2.1</a>). Of note, only the agents idraparinux and idrabiotaparinux were administered parenterally. We only observed a statistically significant decrease for this outcome in people treated with oral factor Xa inhibitors compared with warfarin (OR 0.87, 95% CI 0.80 to 0.96). Overall, we observed no statistically significant differences in the number of strokes and systemic embolic events between the oral and parenteral factor Xa inhibitors (test for subgroup differences: P = 0.59; I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0091"> <h6 class="title">Subgroup analysis 6: major bleedings</h6> <p>The number of major bleedings was lower in people receiving orally administered factor Xa inhibitors compared with warfarin (OR 0.74, 95% CI 0.69 to 0.80: <a href="./references#CD008980-fig-0016" title="">Analysis 2.2</a>). For the parenterally administered factor Xa inhibitors, we observed a statistically significant increase in major bleedings when compared with warfarin (OR 1.82, 95% CI 1.30 to 2.55). We observed a statistically significant difference in the number of major bleedings between the oral and parenteral factor Xa inhibitors (test for subgroup differences: P &lt; 0.00001; I<sup>2</sup> = 96%). </p> </section> </section> <section id="CD008980-sec-0092"> <h5 class="title">Quality of anticoagulation with warfarin</h5> <section id="CD008980-sec-0093"> <h6 class="title">Subgroup analysis 7: stroke and systemic embolic events</h6> <p>We performed a subgroup analysis in people who received warfarin treatment with median time‐in‐therapeutic range (TTR) ≤ 60% versus ≥ 60%, i.e. 'low/bad' versus 'high/good' quality treatment (<a href="./references#CD008980-fig-0021" title="">Analysis 5.1</a>). To perform this analysis for the primary efficacy endpoint, we had sufficient data from the phase III trials of apixaban, rivaroxaban and edoxaban (<a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>), which enrolled 52,695 participants in total. The number of strokes and systemic embolic events was lower among people treated with factor Xa inhibitors compared with warfarin in centres with TTRs ≥ 60%, although this difference did not reach statistical significance (OR 0.89, 95% CI 0.77 to 1.04). In centres with TTRs ≤ 60% the number of strokes and systemic embolic events was again lower in people treated with factor Xa inhibitors and this difference was statistically significant (OR 0.81, 95% CI 0.70 to 0.93). Overall, we did not observe any statistically significant differences between the three compounds in this subgroup analysis (test for subgroup differences: P = 0.34; I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0094"> <h6 class="title">Subgroup analysis 8: major bleedings</h6> <p>We performed a similar subgroup analysis based on the quality of warfarin treatment for major bleedings (<a href="./references#CD008980-fig-0022" title="">Analysis 5.2</a>). Again, we could only include data for apixaban, edoxaban and rivaroxaban from their respective phase III studies (n = 52,730). We observed a lower number of major bleedings with factor Xa inhibitors compared with warfarin (OR 0.80, 95% CI 0.72 to 0.90) in centres with TTRs ≥ 60%. There was, however, high and statistically significant heterogeneity in this analysis (I<sup>2</sup> = 90%; P &lt; 0.0001). A sensitivity analysis using a random‐effects model did not show a statistically significant decrease (OR 0.87, 95% CI 0.60 to 1.27). In centres with TTRs ≤ 60% the risk of major bleedings was lower for the factor Xa inhibitors compared with warfarin (OR 0.69, 95% CI 0.62 to 0.77), but we observed high heterogeneity (I<sup>2</sup> = 88%; P = 0.0002). A sensitivity analysis using a random‐effects model also showed a statistically significant lower risk for the factor Xa inhibitors compared with 'low' quality warfarin treatment (OR 0.67, 95% CI 0.49 to 0.93). Overall, there were no significant differences between the three compounds in this subgroup analysis (test for subgroup differences: P = 0.05; I<sup>2</sup> = 73%). </p> </section> </section> <section id="CD008980-sec-0095"> <h5 class="title">Previous stroke and transient ischaemic attack (TIA)</h5> <section id="CD008980-sec-0096"> <h6 class="title">Subgroup analysis 9: stroke and systemic embolic events</h6> <p>We compared the efficacy of factor Xa inhibitors in participants with or without a previous stroke or TIA (<a href="./references#CD008980-fig-0019" title="">Analysis 4.1</a>). We had data from four compounds (n = 59,247) for this for this subgroup analysis: idraparinux, apixaban, edoxaban and rivaroxaban. The risk of stroke and systemic embolic events was significantly lower in people treated with factor Xa inhibitors who had previously suffered a stroke or TIA (OR 0.87, 95% CI 0.76 to 1.00), and in people who did not have a previous stroke or TIA (OR 0.85, 95% CI 0.74 to 0.97), compared to warfarin. We observed no statistically significant differences in these analyses (test for subgroup differences: P = 0.78; I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0097"> <h6 class="title">Subgroup analysis 10: major bleedings</h6> <p>We performed a similar subgroup analysis for the major bleedings outcome (<a href="./references#CD008980-fig-0020" title="">Analysis 4.2</a>). We were able to include data on three factor Xa inhibitors: apixaban, edoxaban and rivaroxaban (n = 54,615). The number of major bleedings was significantly lower in participants with or without a previous stroke or TIA who received treatment with factor Xa inhibitors compared with warfarin: OR 0.79 (95% CI 0.69 to 0.90) and OR 0.73 (95% CI 0.67 to 0.80), respectively. Overall, we observed no statistically significant differences in these analyses (test for subgroup differences: P = 0.35; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD008980-sec-0098"> <h5 class="title">Prior VKA treatment</h5> <section id="CD008980-sec-0099"> <h6 class="title">Subgroup analysis 11: stroke and systemic embolic events</h6> <p>We analysed the efficacy of factor Xa inhibitors in people who had received prior treatment with a VKA versus those who had not (total n = 59,247). The number of strokes and systemic embolic events was significantly lower with factor Xa inhibitors in people who had not received prior VKA treatment (OR 0.80, 95% CI 0.69 to 0.93), but not in people who had received treatment with a VKA prior to randomisation (OR 0.90, 95% CI 0.79 to 1.02) (<a href="./references#CD008980-fig-0023" title="">Analysis 6.1</a>). We found low, non‐statistically significant heterogeneity in these analyses (test for subgroup differences: P = 0.24; I<sup>2</sup> = 26%). </p> </section> <section id="CD008980-sec-0100"> <h6 class="title">Subgroup analysis 12: major bleedings</h6> <p>A similar analysis for the primary safety endpoint showed a statistically significant lower risk of major bleedings with factor Xa inhibitors in people who had not received prior VKA treatment (OR 0.74, 95% CI 0.66 to 0.84) and in those who had prior VKA treatment (OR 0.75, 95% CI 0.68 to 0.83) (<a href="./references#CD008980-fig-0024" title="">Analysis 6.2</a>). High and statistically significant heterogeneity was observed in the latter analysis (I<sup>2</sup> = 89%; P &lt; 0.00001). Overall however, we observed no statistically significant differences in the analyses (test for subgroup differences: P = 0.85; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD008980-sec-0101"> <h5 class="title">Concomitant antiplatelet therapy</h5> <section id="CD008980-sec-0102"> <h6 class="title">Subgroup analysis 13: stroke and systemic embolic events</h6> <p>We had data to explore the efficacy of the factor Xa inhibitors apixaban and rivaroxaban in people receiving concomitant antiplatelet therapy (<a href="./references#CD008980-fig-0025" title="">Analysis 7.1</a>). The number of strokes and systemic embolic events in people treated with the factor Xa inhibitors was significantly lower regardless of concomitant antiplatelet use at baseline or not: OR 0.81 (95% CI 0.66 to 0.98) and OR 0.69 (95% CI 0.61 to 0.78), respectively. We did, however, observe high and statistically significant heterogeneity in the analysis of the latter subgroup (I<sup>2</sup> = 84%; P = 0.002). A sensitivity analysis with a random‐effects model also showed a statistically significant lower risk of strokes and systemic embolic events in this group (OR 0.58, 95% CI 0.36 to 0.93). Overall, we observed statistically significant differences in the number of stroke and systemic embolic events in this subgroup analysis (P = 0.05; I<sup>2</sup> = 74%). </p> </section> <section id="CD008980-sec-0103"> <h6 class="title">Subgroup analysis 14: major bleedings</h6> <p>The number of major bleedings was significantly lower in people treated with a factor Xa inhibitor who did not receive concomitant antiplatelet therapy at baseline (OR 0.80, 95% CI 0.70 to 0.91) (<a href="./references#CD008980-fig-0026" title="">Analysis 7.2</a>), however, we observed high, statistically significant heterogeneity (I<sup>2</sup> = 75%; P = 0.0008). There was no statistically significant difference in the risk of major bleeding events in people receiving concomitant antiplatelet therapy (OR 0.93, 95% CI 0.80 to 1.09). Again, we observed high heterogeneity (I<sup>2</sup> = 61%; P = 0.08). Sensitivity analyses with a random‐effects model did not show statistically significant differences in these two subgroups: OR 0.78 (95% CI 0.57 to 1.08) versus OR 0.94 (95% CI 0.70 to 1.26), respectively. </p> </section> </section> <section id="CD008980-sec-0104"> <h5 class="title">Age</h5> <section id="CD008980-sec-0105"> <h6 class="title">Subgroup analysis 15: stroke and systemic embolic events</h6> <p>We analysed the efficacy of treatment with some factor Xa inhibitors in two age categories: age less than 75 years versus 75 years or more (<a href="./references#CD008980-fig-0027" title="">Analysis 8.1</a>). The number of strokes and systemic embolic events was significantly lower in people aged 75 years or more with factor Xa inhibitors (OR 0.76, 95% CI 0.66 to 0.88). We found no statistically significant difference in participants aged less than 75 years (OR 0.96, 95% CI 0.84 to 1.09). Overall, there was a statistically significant difference in the number of strokes and systemic embolic events in this subgroup analysis (P = 0.02; I<sup>2</sup> = 80%). </p> </section> <section id="CD008980-sec-0106"> <h6 class="title">Subgroup analysis 16: major bleedings</h6> <p>The number of major bleedings was significantly lower with factor Xa inhibitors in both age categories (<a href="./references#CD008980-fig-0028" title="">Analysis 8.2</a>). Still, high and statistically heterogeneity was observed in both analyses (I<sup>2</sup> = 81% and 89%; P &lt; 0.0001, respectively). Sensitivity analyses with a random‐effects model showed a statistically significant difference in the number of major bleedings in people aged less than 75 years (OR 0.73, 95% CI 0.57 to 0.94), but not in people aged 75 years or more (OR 0.80, 95% CI 0.57 to 1.11). </p> </section> </section> <section id="CD008980-sec-0107"> <h5 class="title">Sex</h5> <section id="CD008980-sec-0108"> <h6 class="title">Subgroup analysis 17: stroke and systemic embolic events</h6> <p>We had data from four compounds to assess the efficacy of factor Xa inhibitors compared with warfarin in women and men. There was a similar and statistically significant reduction of the risk of strokes and systemic embolic events for both women (OR 0.84, 95% CI 0.73 to 0.98) and men (OR 0.87, 95% CI 0.76 to 0.98) treated with factor Xa inhibitors, and no statistically significant differences (<a href="./references#CD008980-fig-0031" title="">Analysis 10.1</a>). Overall, there was no statistically significant difference in the number of strokes and systemic embolic events in this subgroup analysis (P = 0.80; I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0109"> <h6 class="title">Subgroup analysis 18: major bleedings</h6> <p>An analysis of major bleeding events showed a statistically significantly lower risk in both women and men in favour of factor Xa inhibitors compared with warfarin (<a href="./references#CD008980-fig-0032" title="">Analysis 10.2</a>). There was, however, high and statistically significant heterogeneity in both analyses (I<sup>2</sup> = 80% and 78%; P &lt; 0.001, respectively). Pre‐specified sensitivity analyses with a random‐effects model showed no statistically significant differences in the number of bleedings in both sexes (men: OR 0.79, 95% CI 0.63 to 1.01; women: OR 0.72, 95% CI 0.52 to 1.00). </p> </section> </section> <section id="CD008980-sec-0110"> <h5 class="title">Baseline stroke risk (CHADS<sub>2</sub> score) </h5> <section id="CD008980-sec-0111"> <h6 class="title">Subgroup analysis 19: stroke and systemic embolic events</h6> <p>We had data from four agents (apixaban, edoxaban, idraparinux and rivaroxaban) to assess the efficacy in people with different baseline stroke risks based on their CHADS<sub>2</sub> scores (<a href="./references#CD008980-fig-0033" title="">Analysis 11.1</a>). The risk of stroke and systemic embolic events was significantly lower in people with baseline CHADS<sub>2</sub> scores of 3 or more (i.e. high risk of stroke) who were treated with factor Xa inhibitors compared with warfarin (OR 0.81, 95% CI 0.72 to 0.92). No statistically significant differences were observed in people with baseline CHADS<sub>2</sub> scores of 0 to 1 (OR 0.90, 95% CI 0.61 to 1.32) and 2 (OR 0.92, 95% CI 0.78 to 1.08). Overall, there was no statistically significant difference in the number of strokes and systemic embolic events in this subgroup analysis (P = 0.49; I<sup>2</sup> = 0%). </p> </section> <section id="CD008980-sec-0112"> <h6 class="title">Subgroup analysis 20: major bleedings</h6> <p>We also analysed the risk of major bleedings by baseline CHADS<sub>2</sub> score (<a href="./references#CD008980-fig-0034" title="">Analysis 11.2</a>). In all three subcategories there were significantly lower numbers of major bleedings in participants treated with factor Xa inhibitors compared with warfarin (CHADS<sub>2</sub> score 0 to 1: OR 0.69 (95% CI 0.53 to 0.90); CHADS<sub>2</sub> score 2: OR 0.71 (95% CI 0.63 to 0.80); and CHADS<sub>2</sub> score 3 or more: OR 0.88 (95% CI 0.79 to 0.98)). There was, however, high and statistically significant heterogeneity in these analyses (I<sup>2</sup> ranging from 77% to 95%; P values &lt; 0.001). Sensitivity analyses with a random‐effects model did not show any statistically significant differences in the number of bleedings between factor Xa inhibitors and warfarin in any of the subgroups: CHADS<sub>2</sub> score 0 to 1: OR 1.34 (95% CI 0.20 to 9.09); CHADS<sub>2</sub> score 2: OR 0.92 (95% CI 0.63 to 1.35); and CHADS<sub>2</sub> score 3 or more: OR 0.91 (95% CI 0.70 to 1.19). </p> </section> </section> <section id="CD008980-sec-0113"> <h5 class="title">Race</h5> <section id="CD008980-sec-0114"> <h6 class="title">Subgroup analysis 21: stroke and systemic embolic events</h6> <p>Most people included in the studies were either Asian (22%) or White (74%). We only observed a statistically significant lower number of stroke and systemic embolic events in Asian people treated with factor Xa inhibitors compared with warfarin (OR 0.73, 95% CI 0.56 to 0.94: <a href="./references#CD008980-fig-0029" title="">Analysis 9.1</a>). Overall, there was no statistically significant difference in the number of strokes and systemic embolic events in this subgroup analysis (P = 0.36; I<sup>2</sup> = 62%). </p> </section> <section id="CD008980-sec-0115"> <h6 class="title">Subgroup analysis 22: major bleedings</h6> <p>We observed statistically significant lower numbers of major bleedings in all races included in the studies treated with factor Xa inhibitors, but not in Black people (OR 0.91, 95% CI 0.45 to 1.87: <a href="./references#CD008980-fig-0030" title="">Analysis 9.2</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008980-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008980-sec-0116"></div> <section id="CD008980-sec-0117"> <h3 class="title" id="CD008980-sec-0117">Summary of main results</h3> <section id="CD008980-sec-0118"> <h4 class="title">Primary and secondary analyses</h4> <p>We analysed data from 67,688 people with a confirmed diagnosis of atrial fibrillation (AF), who were included in 13 trials that examined the efficacy and safety of long‐term anticoagulation with a factor Xa inhibitor compared with vitamin K antagonists (VKAs). </p> <p>Treatment with factor Xa inhibitors significantly reduced the number of strokes and systemic embolic events compared with dose‐adjusted warfarin. Still, the absolute overall effect in the reduction of stroke and systemic embolic events with factor Xa inhibitors was rather small, as shown by the high NNTs and NNTHs observed in the phase III studies of apixaban, rivaroxaban and edoxaban. The number of ischaemic strokes only was not significantly different when comparing the various factor Xa inhibitors with warfarin, although studies were not adequately powered for this subgroup analysis. </p> <p>An analysis of all factor Xa inhibitors showed a statistically significant reduced risk of major bleedings compared with warfarin. However, there was a moderate to high degree of heterogeneity between the included studies. A pre‐specified sensitivity analysis excluding all open‐label studies showed that part of the observed heterogeneity was caused by the increased risk of major bleedings in one open‐label study of subcutaneously administered idraparinux (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>). This study was stopped prematurely because of an increased risk of bleeding in the idraparinux treatment arm. Due to the premature termination of this study it is difficult to assess whether this was a false positive finding, or whether there is indeed an increased risk of bleeding associated with idraparinux. Other heterogeneity might be explained by baseline differences in the risk of bleeding between the study populations enrolled into the three largest trials that accounted for approximately 90% of the data included in this review (<a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a>; <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>). When compared with people enrolled into <a href="./references#CD008980-bbs2-0002" title="GrangerCB , AlexanderJH , McMurrayJJ , LopesRD , HylekEM , HannaM , et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365:981‐92. ">ARISTOTLE 2011</a> and <a href="./references#CD008980-bbs2-0008" title="GiuglianoRP , RuffCT , BraunwaldE , MurphySA , WiviottSD , HalperinJL , et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2013;369:2093‐104. ">ENGAGE AF‐TIMI 48 2013</a>, people enrolled into <a href="./references#CD008980-bbs2-0013" title="PatelMR , MahaffeyKW , GargY , PanG , SingerDE , HackeW , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365:883‐91. ">ROCKET AF 2011</a> were generally older (median age 70 and 72 years, versus 73 years), had higher baseline CHADS<sub>2</sub> scores (mean 2.1 and 2.8, versus 3.8), had more often suffered a previous stroke or transient ischaemic attack (TIA) (19% and 28%, versus 55%), and more often used aspirin at baseline (31% and 29%, versus 38%). These are all known risk factors for (major) bleedings during anticoagulant treatment (<a href="./references#CD008980-bbs2-0062" title="PistersR , LaneDA , NieuwlaatR , DeVosCB , CrijnsHJ , LipGY . A novel user‐friendly score (HAS‐BLED) to assess 1‐year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest2010;138(5):1093‐100. ">Pisters 2010</a>). In addition, the observed heterogeneity might also be partly explained by differences in the characteristics and bleeding profiles of apixaban, edoxaban and rivaroxaban. </p> <p>Importantly, the number of intracranial haemorrhages (ICHs) was significantly lower in people treated with factor Xa inhibitors compared with warfarin. We observed high and statistically significant heterogeneity in this analysis, which appeared to be mainly caused by the increased number of ICHs in the prematurely halted open‐label study of idraparinux (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a>). A pre‐specified sensitivity analysis, in which we excluded data from this open‐label study, showed a clinically relevant and statistically significant reduction of the number of ICHs in people treated with a factor Xa inhibitor compared with warfarin without any signs of heterogeneity. </p> <p>Treatment with factor Xa inhibitors also significantly reduced the number of deaths compared with warfarin, though this outcome was not reported in three smaller trials and was missing or unknown for a small number of participants (up to 2.1% ) in some of the other trials. Treatment with factor Xa inhibitors also did not appear to be associated with an increased risk of acute myocardial infarctions or vascular deaths compared with warfarin. </p> </section> <section id="CD008980-sec-0119"> <h4 class="title">Subgroup analyses</h4> <p>Generally, the subgroup analyses for stroke and systemic embolic events supported the results from the main analysis, though no statistically significant reduction was seen in some important subgroups (e.g. people who had previously received VKA treatment, people aged under 75 years, and people with baseline CHADS<sub>2</sub> scores of less than 3). The difference in major bleedings in most subgroups was also in line with findings from the main analysis that showed a statistically significant reduction with factor Xa inhibitors. High heterogeneity was, however, observed in many of the subgroup analyses for this outcome. Furthermore, many of the included subgroups (i.e. different dose levels of factor Xa inhibitors) contained no, or only very few, events and should therefore be interpreted cautiously. </p> <p>We also performed a subgroup analysis comparing outcomes in people treated with apixaban, edoxaban and rivaroxaban versus 'high' and 'low' quality warfarin treatment. This analysis showed that a statistically significant reduction of thromboembolic events in people receiving these factor Xa inhibitors was only observed in comparison with 'low' quality warfarin treatment, although overall there was no statistically significant difference between these two subgroups. The number of major bleedings was significantly lower with these three factor Xa inhibitors regardless of the quality of the warfarin treatment. It should, however, be noted that the evidence for a reduction in bleedings compared with 'high' quality warfarin treatment is less robust due to high and statistically significant heterogeneity between the three factor Xa inhibitors included in this subgroup analysis. Interpretation of these analyses requires further caution since none of the included studies were adequately powered to detect differences between these subgroups. </p> </section> <section id="CD008980-sec-0120"> <h4 class="title"><i>Summary</i> </h4> <p>In summary, factor Xa inhibitors appear to be an effective treatment for the prevention of stroke or systemic embolic events in people with AF who are eligible for long‐term anticoagulation. The absolute effect of factor Xa inhibitors compared with warfarin treatment was, however, rather small. Treatment with factor Xa inhibitors was associated with a reduction of deaths, ICHs and major bleedings compared with warfarin, although the evidence for a statistically significant reduction in major bleedings is less robust due to high heterogeneity between the included studies. Finally, even though effect estimates varied for the different factor Xa inhibitors, it is currently not possible to accurately determine which factor Xa inhibitor is the most effective and safe as head‐to‐head studies have not been performed. </p> </section> </section> <section id="CD008980-sec-0121"> <h3 class="title" id="CD008980-sec-0121">Overall completeness and applicability of evidence</h3> <p>All data that were used in this review are derived from studies that randomised people with a confirmed diagnosis of AF, who were all deemed eligible for long‐term anticoagulation with warfarin by the randomising physician. The mean CHADS<sub>2</sub> score of the randomised participants was around 2.7 (range 1.9 to 3.5), suggesting that few, if any, people with AF who did not need anticoagulation for prevention of thromboembolic events (a so‐called 'truly low risk population') were included in the studies. Reported median time in therapeutic range (TTR) values ranged from 45% to 89% in the included studies, but varied between regions and study centres. In general, the observed TTRs are comparable with those seen in older studies that used dose‐adjusted warfarin for preventing stroke and systemic embolic events in people with AF, and with data from clinical practice. The majority of included studies did not state an upper age limit as a contraindication and the mean and median ages of randomised participants ranged between 65 and 74 years. Based on these observations, we can be reasonably confident that this review covers a clinically relevant population of people with AF eligible for long‐term anticoagulation that also appears generalisable to a 'real world' setting. </p> <p>The CHA2DS2‐VASc score was not used in any of the included studies to assess the risk of stroke. Recent guidelines prefer the use of this score over the simpler CHADS<sub>2</sub> score and recommend that anticoagulation with either an oral anticoagulant (i.e. apixaban, dabigatran, edoxaban or rivaroxaban) or a VKA should be considered in people with a CHA2DS2‐VASc score of 1 or more in men and 2 or more in women (<a href="./references#CD008980-bbs2-0022" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , ClevelandJC , CigarroaJE , et al. Guidelines for the management of patients with atrial fibrillation. Circulation2014; Vol. 129. [DOI: 10.1161/CIR.000000000000000041] ">ACC/AHA/HRS 2014</a>; <a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>). There is some evidence that the CHA2DS2‐VASc scale is better at identifying people with a 'very low' risk of stroke than the older CHADS<sub>2</sub> score (<a href="./references#CD008980-bbs2-0037" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37:2893‐962. ">ESC 2016</a>). Consequently, data from people who are at a 'very low' risk of stroke are most probably not included in this review. Caution is thus needed when drawing any conclusions on the effectiveness and safety of factor Xa inhibitors in people that fall into this 'very low risk' category. </p> <p>Data on participants with severe renal failure (i.e. creatinine clearance &lt; 30 ml/minute) and on haemodialysis, who are known to have a higher risk of both thromboembolic events and bleedings, are also scarce in this review because these people were excluded from participation in most of the included trials. </p> <p>Finally, we have included data from seven different factor Xa inhibitors in this review. Still, the majority of the data (approximately 90%) are from only three factor Xa inhibitors: apixaban, edoxaban and rivaroxaban. Results from the presented analyses of the other factor Xa inhibitors are based on smaller data sets and therefore considered less robust. </p> </section> <section id="CD008980-sec-0122"> <h3 class="title" id="CD008980-sec-0122">Quality of the evidence</h3> <p>The studies included in this review were generally large to very large; the smallest study enrolled 222 participants. Only one of the 13 included studies was conducted in an open‐label fashion. The remaining studies were either double‐masked or partially‐masked. Most studies used centralised, blinded adjudication committees for the assessments of the primary safety and efficacy outcomes. Furthermore, outcome data from the (larger) studies appear generally consistent. Based on these considerations, the overall quality of the body of evidence assessed in this review is considered high. </p> </section> <section id="CD008980-sec-0123"> <h3 class="title" id="CD008980-sec-0123">Potential biases in the review process</h3> <p>We contacted lead authors and sponsors in order to gather any non‐reported data from relevant studies. Disappointingly, such additional data were only provided for two studies (<a href="./references#CD008980-bbs2-0001" title="The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371:315‐21. ">AMADEUS 2008</a> and <a href="./references#CD008980-bbs2-0010" title="HoriM , MatsumotoM , TanahashiN , MomomuraSI , UchiyamaS , GotoS , J‐ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal2012;76(9):2104‐11. [DOI: 10.1253/circj.CJ‐12‐0454] ">J‐ROCKET AF 2012</a>). </p> <p>We also used data from licensing applications that were submitted to the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the compounds apixaban, edoxaban and rivaroxaban in our analyses. Data from these three compounds comprise approximately 90% of all data that were analysed in our review. The use of these unpublished data has significantly decreased the potential for publication biases in our review. </p> <p>We also carried out thorough searches of several different databases to further avoid selection bias. There is, however, a small possibility that we still might have missed some (smaller) studies. </p> </section> <section id="CD008980-sec-0124"> <h3 class="title" id="CD008980-sec-0124">Agreements and disagreements with other studies or reviews</h3> <p>We compared our findings with the results from several other recently published meta‐analyses and systematic reviews that examined the efficacy and safety of factor Xa inhibitors compared with warfarin in people with AF (<a href="./references#CD008980-bbs2-0024" title="Biondi‐ZoccaiG , MalavasiV , D’AscenzoF , AbbateA , AgostoniP , LotrionteM , et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair‐wise and warfarin‐controlled network meta‐analyses. HSR Proceedings in Intensive Care and Cardiovascular Anesthesia2013;5(1):40‐54. ">Biondi‐Zoccai 2013</a>; <a href="./references#CD008980-bbs2-0028" title="CapodannoD , CapranzanoP , GiacchiG , CalviV , TamburinoC . Novel oral anticoagulants versus warfarin in non‐valvular atrial fibrillation: a meta‐analysis of 50,578 patients. International Journal of Cardiology2013;167(4):1237‐41. [DOI: 10.1016/j.ijcard.2012.03.148] ">Capodanno 2013</a>; <a href="./references#CD008980-bbs2-0034" title="DogliottiA1 , PaolassoE , GiuglianoRP . Novel oral anticoagulants in atrial fibrillation: a meta‐analysis of large, randomized, controlled trials vs warfarin. Clinical Cardiology2013;36(2):61‐7. [DOI: 10.1002/clc.22081] ">Dogliotti 2013</a>; <a href="./references#CD008980-bbs2-0051" title="KwongJS , LamYY , YanBP , YuCM . Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta‐analysis of randomized controlled trials. Cardiovascular Drugs and Therapy2013;27(1):23‐35. [DOI: 10.1007/s10557‐012‐6426‐9] ">Kwong 2013</a>; <a href="./references#CD008980-bbs2-0052" title="LegaJC , MismettiP , CucheratM , et al. Impact of double‐blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis. Journal of Thrombosis and Haemostasis2013;11(7):1240‐50. [DOI: 10.1111/jth.12294] ">Lega 2013</a>; <a href="./references#CD008980-bbs2-0058" title="MitchellSA , SimonTA , RazaS , JakouloffD , OrmeME , LockhartI , et al. The efficacy and safety of oral anticoagulants in warfarin‐suitable patients with nonvalvular atrial fibrillation: systematic review and meta‐analysis. Clinical and Applied Thrombosis/Hemostasis2013;19(6):619‐31. [DOI: 10.1177/1076029613486539] ">Mitchell 2013</a>; <a href="./references#CD008980-bbs2-0067" title="TahirF , RiazH , RiazT , BadshahMB , RiazIB , HamzaA , et al. The new oral anti‐coagulants and the phase 3 clinical trials ‐ a systematic review of the literature. Thrombosis Journal2013;11(1):18. ">Tahir 2013</a>; <a href="./references#CD008980-bbs2-0027" title="CameronC , CoyleD , RichterT , KellyS , GauthierK , SteinerS , et al. Systematic review and network meta‐analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open2014;4(6):e004301. [DOI: 10.1136/bmjopen‐2013‐004301] ">Cameron 2014</a>; <a href="./references#CD008980-bbs2-0038" title="FuW , GuoH , GuoJ , LinK , WangH , ZhangY , et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta‐analysis. Journal of Cardiovascular Medicine2014;12(15):873‐9. ">Fu 2014</a>; <a href="./references#CD008980-bbs2-0063" title="ProvidênciaR , GroveEL , HustedS , BarraS , BovedaS , MoraisJ . A meta‐analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thrombosis Research2014;134(6):1253‐64. [DOI: 10.1016/j.thromres.2014.10.002] ">Providencia 2014</a>; <a href="./references#CD008980-bbs2-0065" title="RuffCT , GiuglianoRP , BraunwaldE , HoffmanEB , DeenadayaluN , EzekowitzMD , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta‐analysis of randomised trials. Lancet2014;15(383):955‐62. [DOI: 10.1016/S0140‐6736(13)62343‐0] ">Ruff 2014</a>; <a href="./references#CD008980-bbs2-0026" title="CaldeiraD , RodriguesFB , BarraM , SantosAT , deAbreuD , GoncalvesN . Non‐vitamin K antagonist oral anticoagulants and major bleeding‐related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta‐analysis. Heart2015;15(101):1204‐11. ">Caldeira 2015</a>; <a href="./references#CD008980-bbs2-0041" title="Gomez‐OutesA , Suarez‐GeaML , Terleira‐FernandezAI , Vargas‐CastrillonE , Calvo‐RojasG . Direct oral anticoagulants versus warfarin for stroke prevention in atrial fibrillation: a subgroup meta‐analysis in European patients. Clinical Therapeutics2015;37(8 Suppl):e10. ">Gomez‐Outes 2015</a>; <a href="./references#CD008980-bbs2-0053" title="LinL , LimWS , ZhouHJ , KhooAL , TanKT , ChewAP , et al. Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation: a systematic review and network meta‐analysis. Journal of the American Medical Directors Association2015;16(12):1103.e1‐19. ">Lin 2015</a>; <a href="./references#CD008980-bbs2-0060" title="MorimotoT , CrawfordB , WadaK , UedaS . Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta‐analysis with the adjustment for the possible bias from open label studies. Journal of Cardiology2015;66(6):466‐74. ">Morimoto 2015</a>; <a href="./references#CD008980-bbs2-0023" title="AlmutairiA , ZhouL , LeeJK , MarionS , MartinJR , Lo‐CiganicW . Comparative effectiveness and safety of novel oral anticoagulants (NOACS) versus vitamin K antagonists (VKA) in atrial fibrillation: a meta‐analysis of observational studies. Value Health2016;3(19):A41. ">Almutairi 2016</a>; <a href="./references#CD008980-bbs2-0039" title="GargJ , ChaudharyR , KrishnamoorthyP , PalaniswamyC , ShahN , BozorgniaB , et al. Safety and efficacy of oral factor‐Xa inhibitors versus vitamin K antagonist in patients with non‐valvular atrial fibrillation. International Journal of Cardiology2016;218:235‐9. ">Garg 2016</a>; <a href="./references#CD008980-bbs2-0054" title="LipGYH , MitchellSA , LiuX , LiuLZ , PhatakH , KachrooS , et al. Relative efficacy and safety of non‐Vitamin K oral anticoagulants for non‐valvular atrial fibrillation: network meta‐analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Internaitonal Journal of Cardiology2016;204:88‐94. ">Lip 2016</a>; <a href="./references#CD008980-bbs2-0055" title="LiuL , WeberB , OesterleA , NayakHM , UpadhyayGA . A meta‐analysis of the efficacy, effectiveness, and safety of novel oral anticoagulants compared with vitamin K antagonists for stroke prevention in atrial fibrillation. Heart Rhythm2016;1:S599. ">Liu 2016</a>; <a href="./references#CD008980-bbs2-0068" title="TawfikA , BieleckiJM , KrahnM , DorianP , HochJS , BoonH , et al. Systematic review and network meta‐analysis of stroke prevention treatments in patients with atrial fibrillation. Clinical Pharmacology2016;8:93‐107. ">Tawfik 2016</a>; <a href="./references#CD008980-bbs2-0072" title="XiangCL , GongYZ , ZengLJ , WangR , KeaS , ChaudharyN , et al. Efficacy and safety or oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta‐analysis of randomized controlled trials. Acta Cardiologica2016;71(3):349‐57. ">Xiang 2016</a>). Findings from these studies are generally in agreement with the findings and conclusions from our review, notably for the primary efficacy and safety outcomes. These meta‐analyses and reviews were, however, less comprehensive than our review because they all included data from fewer studies and fewer factor Xa inhibitors, performed fewer (subgroup) analyses and also did not appear to have used unpublished data that were submitted to regulatory bodies (i.e. EMA and FDA). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008980-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008980-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD008980-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD008980-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 2 All strokes." data-id="CD008980-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 2 All strokes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 3 Ischaemic stroke." data-id="CD008980-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 3 Ischaemic stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 4 Disabling or fatal stroke." data-id="CD008980-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 4 Disabling or fatal stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 5 Systemic embolic events (non‐CNS)." data-id="CD008980-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 5 Systemic embolic events (non‐CNS).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 6 Major bleedings." data-id="CD008980-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 6 Major bleedings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 7 Intracranial haemorrhages." data-id="CD008980-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 7 Intracranial haemorrhages.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 8 Non‐major clinically relevant bleeds." data-id="CD008980-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 8 Non‐major clinically relevant bleeds. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 9 Myocardial infarction." data-id="CD008980-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 9 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 10 Vascular deaths." data-id="CD008980-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 10 Vascular deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Factor Xa inhibitors versus VKA, Outcome 11 All‐cause deaths." data-id="CD008980-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Factor Xa inhibitors versus VKA, Outcome 11 All‐cause deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Factor Xa inhibitors versus VKA: route of administration, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Factor Xa inhibitors versus VKA: route of administration, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Factor Xa inhibitors versus VKA: route of administration, Outcome 2 Major bleedings." data-id="CD008980-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Factor Xa inhibitors versus VKA: route of administration, Outcome 2 Major bleedings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Factor Xa inhibitors versus VKA: dose of Factor Xa inhibitor, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Factor Xa inhibitors versus VKA: dose of Factor Xa inhibitor, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Factor Xa inhibitors versus VKA: dose of Factor Xa inhibitor, Outcome 2 Major bleedings." data-id="CD008980-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Factor Xa inhibitors versus VKA: dose of Factor Xa inhibitor, Outcome 2 Major bleedings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Factor Xa inhibitors versus VKA: previous stroke or TIA, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Factor Xa inhibitors versus VKA: previous stroke or TIA, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Factor Xa inhibitors versus VKA: previous stroke or TIA, Outcome 2 Major bleedings." data-id="CD008980-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Factor Xa inhibitors versus VKA: previous stroke or TIA, Outcome 2 Major bleedings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Factor Xa inhibitors versus VKA: quality of anticoagulation with VKA (TTR), Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Factor Xa inhibitors versus VKA: quality of anticoagulation with VKA (TTR), Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Factor Xa inhibitors versus VKA: quality of anticoagulation with VKA (TTR), Outcome 2 Major bleedings." data-id="CD008980-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Factor Xa inhibitors versus VKA: quality of anticoagulation with VKA (TTR), Outcome 2 Major bleedings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Factor Xa inhibitors versus VKA: previous VKA use, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Factor Xa inhibitors versus VKA: previous VKA use, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Factor Xa inhibitors versus VKA: previous VKA use, Outcome 2 Major bleedings." data-id="CD008980-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Factor Xa inhibitors versus VKA: previous VKA use, Outcome 2 Major bleedings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Factor Xa inhibitors versus VKA: concomitant antiplatelet use, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Factor Xa inhibitors versus VKA: concomitant antiplatelet use, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Factor Xa inhibitors versus VKA: concomitant antiplatelet use, Outcome 2 Major bleedings." data-id="CD008980-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Factor Xa inhibitors versus VKA: concomitant antiplatelet use, Outcome 2 Major bleedings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Factor Xa inhibitors versus VKA: age, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Factor Xa inhibitors versus VKA: age, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Factor Xa inhibitors versus VKA: age, Outcome 2 Major bleedings." data-id="CD008980-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Factor Xa inhibitors versus VKA: age, Outcome 2 Major bleedings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Factor Xa inhibitors versus VKA: race, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Factor Xa inhibitors versus VKA: race, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Factor Xa inhibitors versus VKA: race, Outcome 2 Major bleedings." data-id="CD008980-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Factor Xa inhibitors versus VKA: race, Outcome 2 Major bleedings.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Factor Xa inhibitors versus VKA: sex, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Factor Xa inhibitors versus VKA: sex, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Factor Xa inhibitors versus VKA: sex, Outcome 2 Major bleeding." data-id="CD008980-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Factor Xa inhibitors versus VKA: sex, Outcome 2 Major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Factor Xa inhibitors versus VKA: baseline CHADS2 score, Outcome 1 Stroke and other systemic embolic events." data-id="CD008980-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Factor Xa inhibitors versus VKA: baseline CHADS2 score, Outcome 1 Stroke and other systemic embolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008980-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/urn:x-wiley:14651858:media:CD008980:CD008980-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_t/tCD008980-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Factor Xa inhibitors versus VKA: baseline CHADS2 score, Outcome 2 Major bleedings." data-id="CD008980-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Factor Xa inhibitors versus VKA: baseline CHADS2 score, Outcome 2 Major bleedings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/media/CDSR/CD008980/image_n/nCD008980-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008980-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor Xa inhibitors compared with vitamin K antagonists for preventing stroke and other systemic embolic events in patient with atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment </p> <p><b>Settings:</b> hospital‐based setting </p> <p><b>Intervention:</b> factor Xa inhibitor<sup>1</sup> </p> <p><b>Comparison:</b> dose‐adjusted vitamin K antagonist<sup>2</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Warfarin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Factor Xa inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke and other systemic embolic events</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> <p>(33 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> </p> <p>(0.82 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67477<br/> (13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All strokes</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> <p>(29 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> </p> <p>(0.81 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67449<br/> (13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleedings</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> <p>(43 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b> </p> <p><b>(</b>0.73 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67396<br/> (13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intracranial haemorrhages</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> <p>(8 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.50</b> </p> <p>(0.42 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66259<br/> (12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause deaths</b> </p> <p>Follow‐up: 12 weeks to 2.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> <p>(67 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.89</b> </p> <p>(0.83 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65624<br/> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most data (90%) from studies of apixaban, edoxaban and rivaroxaban</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1 The 13 studies included in this review studied the following types of oral and parenteral factor Xa inhibitors: edoxaban, rivaroxaban, apixaban, edoxaban, betrixaban, darexaban, idraparinux and idrabiotaparinux. Assumed risk calculated from pooled data from warfarin treatment arms (mean) of included studies.</sup> </p> <p><sup>2 All included studies used warfarin with a target INR 2.0‐3.0 as active comparator. Three studies performed in Japan had a target INR of 1.6‐2.6 and 2.0‐2.6 in participants aged &gt; 70 years.</sup> </p> <p><sup>3 High, statistically significant heterogeneity was observed in the initial analysis and in pre‐specified sensitivity analysis excluding all open‐label studies (i.e. the prematurely halted AMADEUS trial). Some other heterogeneity might be explained by baseline differences in the included populations in the three largest trials (ROCKET AF, ENGAGE TIMI‐AF and ARISTOTLE). See section <i>Effects of Interventions, Major bleedings</i> for further discussion.</sup> </p> <p><sup>4 High, statistically significant heterogeneity was observed in the initial analysis. No statistically significant heterogeneity was observed in a pre‐specified sensitivity analysis in which data from all open‐label studies were excluded (i.e. prematurely halted AMADEUS trial).</sup> </p> <p><sup>5 Outcome not reported in three trials and was missing/unknown for some randomised participants (up to 2.1% ) in some of the other included trials.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/full#CD008980-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Factor Xa inhibitors versus VKA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.29, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.08, 35.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.49, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All strokes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.08, 35.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.31, 10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.51, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.18, 13.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.04, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.32, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.08, 35.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.29, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Disabling or fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.14, 10.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.54, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Systemic embolic events (non‐CNS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.48, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.44, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.04, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.59, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.11, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.73, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.60, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.27, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.56, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [1.70, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.05, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.52, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Intracranial haemorrhages <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.42, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.30, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.15, 5.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.30, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.10 [1.43, 86.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.45, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐major clinically relevant bleeds <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.58, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Darexaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.14, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.60, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.23, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.20, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.39, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.66, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.59, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.63, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Darexaban vs VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.28, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Vascular deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.79, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.43, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Darexaban vs VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [0.16, 56.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All‐cause deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.83, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Apixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Betrixaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Idraparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.71, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Rivaroxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Edoxaban versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Darexaban vs VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.36 [0.24, 77.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Idrabiotaparinux versus VKA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Factor Xa inhibitors versus VKA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Factor Xa inhibitors versus VKA: route of administration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.51, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.73, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.69, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.30, 2.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Factor Xa inhibitors versus VKA: route of administration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Factor Xa inhibitors versus VKA: dose of Factor Xa inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.85, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Apixaban 2.5mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Apixaban 5 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Edoxaban 30mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.98, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Edoxaban 45mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.11, 69.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Edoxaban 60mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Edoxaban 30mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.20, 5.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Edoxaban 60mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.05, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Rivaroxaban 10mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.38, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Rivaroxaban 15mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.14, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 Darexaban 15mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.09, 11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Darexaban 30mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.09, 11.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Darexaban 30mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.09, 11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Darexaban 60mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.25, 9.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14 Darexaban 60mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.28, 14.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15 Darexaban 120mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.15, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16 Darexaban 240mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.66 [0.15, 91.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17 Idraparinux 1,5mg once weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18 Idraparinux 2,5mg once weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19 Betrixaban 40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20 Betrixaban 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.12, 74.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21 Betrixaban 80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.12, 74.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22 Idrabiotaparinux 3mg once weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.49, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.65, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Apixaban 2.5mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Apixaban 5mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.61, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Edoxaban 30mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.40, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Edoxaban 45mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.68 [0.34, 130.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Edoxaban 60mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.69, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Edoxaban 30mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.21 [0.60, 44.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Edoxaban 60mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.59 [1.02, 71.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Darexaban 15mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Darexaban 30mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Darexaban 30mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.20, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Darexaban 60mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.10, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Darexaban 60mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.40, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Darexaban 120mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.29, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Darexaban 240mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.66 [0.15, 91.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Rivaroxaban 10mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.71, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 Rivaroxaban 15mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17 Betrixaban 40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18 Betrixaban 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19 Betrixaban 80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.14, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20 Idrabiotaparinux 3mg once weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.52, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21 Idraparinux 1.5/2.5mg once weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [1.70, 4.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Factor Xa inhibitors versus VKA: dose of Factor Xa inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Factor Xa inhibitors versus VKA: previous stroke or TIA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Previous stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No previous stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.70, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Previous stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.69, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 No previous stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.67, 0.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Factor Xa inhibitors versus VKA: previous stroke or TIA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Factor Xa inhibitors versus VKA: quality of anticoagulation with VKA (TTR)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Good quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Bad quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.68, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Good quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.72, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bad quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.62, 0.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Factor Xa inhibitors versus VKA: quality of anticoagulation with VKA (TTR)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Factor Xa inhibitors versus VKA: previous VKA use</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 VKA naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 VKA experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.69, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 VKA naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.66, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 VKA experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.68, 0.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Factor Xa inhibitors versus VKA: previous VKA use</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Factor Xa inhibitors versus VKA: concomitant antiplatelet use</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.61, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Concomitant antiplatelet use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.66, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No concomitant antiplatelet use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.54, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Concomitant antiplatelet use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 No concomitant antiplatelet use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.70, 0.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Factor Xa inhibitors versus VKA: concomitant antiplatelet use</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Factor Xa inhibitors versus VKA: age</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.79, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Age &lt; 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Age ≥ 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.66, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.69, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Age &lt; 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.64, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Age ≥ 75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Factor Xa inhibitors versus VKA: age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Factor Xa inhibitors versus VKA: race</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Asian participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.56, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 White participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Black participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.36, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Other races</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.69, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Asian participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.49, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 White participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.73, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Black participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.45, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Other races</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Factor Xa inhibitors versus VKA: race</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Factor Xa inhibitors versus VKA: sex</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.69, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.71, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.61, 0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Factor Xa inhibitors versus VKA: sex</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008980-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Factor Xa inhibitors versus VKA: baseline CHADS2 score</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke and other systemic embolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CHADS2‐score 0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.61, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 CHADS2‐score 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 CHADS2‐score ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.73, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CHADS2‐score 0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.53, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 CHADS2‐score 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.63, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 CHADS2‐score ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Factor Xa inhibitors versus VKA: baseline CHADS2 score</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008980.pub3/references#CD008980-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008980.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008980-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008980-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008980-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008980-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD008980-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008980-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008980-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008980\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008980\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008980\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008980\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008980\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008980.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008980.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008980.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008980.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008980.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714825294"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008980.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714825297"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008980.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d781f7ddd937d',t:'MTc0MDcxNDgyNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 